Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
285K characters. Original on sec.gov · Markdown
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
ANTHEM, INC.
CONSOLIDATED FINANCIAL STATEMENTS
Years ended December 31, 2018, 2017 and 2016
Contents
| Report of Independent Registered Public Accounting Firm | 71 |
| Audited Consolidated Financial Statements: | |
| Consolidated Balance Sheets | 72 |
| Consolidated Statements of Income | 73 |
| Consolidated Statements of Comprehensive Income | 74 |
| Consolidated Statements of Cash Flows | 75 |
| Consolidated Statements of Shareholders’ Equity | 76 |
| Notes to Consolidated Financial Statements | 77 |
-70-
Report of Independent Registered
Public Accounting Firm
To the Shareholders and the Board of Directors of Anthem, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Anthem, Inc. (the Company) as of December 31, 2018 and 2017, the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2018, and the related notes and financial statement schedule listed in the Index at Item 15(c) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 20, 2019 expressed an unqualified opinion thereon.
Adoption of New Accounting Standard
As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for non-consolidated equity investments not accounted for under the equity method of accounting by requiring changes in fair value to be recognized in income for the year ended December 31, 2018.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ ERNST & YOUNG LLP
We have served as the Company’s auditor since 1944.
Indianapolis, Indiana
February 20, 2019
-71-
Anthem, Inc.
Consolidated Balance Sheets
| December 31, 2018 | December 31, 2017 | ||||||
| (In millions, except share data) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 3,934 | $ | 3,609 | |||
| Fixed maturity securities, current (amortized cost of $16,894 and $17,055) | 16,692 | 17,377 | |||||
| Equity securities, current | 1,493 | 3,599 | |||||
| Other invested assets, current | 21 | 17 | |||||
| Accrued investment income | 162 | 163 | |||||
| Premium receivables | 4,465 | 3,605 | |||||
| Self-funded receivables | 2,278 | 2,580 | |||||
| Other receivables | 2,558 | 2,267 | |||||
| Income taxes receivable | 10 | 342 | |||||
| Securities lending collateral | 604 | 455 | |||||
| Other current assets | 2,104 | 2,249 | |||||
| Total current assets | 34,321 | 36,263 | |||||
| Long-term investments: | |||||||
| Fixed maturity securities (amortized cost of $486 and $555) | 487 | 561 | |||||
| Equity securities | 33 | 33 | |||||
| Other invested assets | 3,726 | 3,344 | |||||
| Property and equipment, net | 2,735 | 2,175 | |||||
| Goodwill | 20,504 | 19,231 | |||||
| Other intangible assets | 9,007 | 8,368 | |||||
| Other noncurrent assets | 758 | 565 | |||||
| Total assets | $ | 71,571 | $ | 70,540 | |||
| Liabilities and shareholders’ equity | |||||||
| Liabilities | |||||||
| Current liabilities: | |||||||
| Policy liabilities: | |||||||
| Medical claims payable | $ | 7,454 | $ | 7,992 | |||
| Reserves for future policy benefits | 75 | 70 | |||||
| Other policyholder liabilities | 2,590 | 2,950 | |||||
| Total policy liabilities | 10,119 | 11,012 | |||||
| Unearned income | 902 | 860 | |||||
| Accounts payable and accrued expenses | 4,959 | 5,024 | |||||
| Security trades pending payable | 197 | 113 | |||||
| Securities lending payable | 604 | 454 | |||||
| Short-term borrowings | 1,145 | 1,275 | |||||
| Current portion of long-term debt | 849 | 1,275 | |||||
| Other current liabilities | 3,190 | 3,343 | |||||
| Total current liabilities | 21,965 | 23,356 | |||||
| Long-term debt, less current portion | 17,217 | 17,382 | |||||
| Reserves for future policy benefits, noncurrent | 706 | 647 | |||||
| Deferred tax liabilities, net | 1,960 | 1,727 | |||||
| Other noncurrent liabilities | 1,182 | 925 | |||||
| Total liabilities | 43,030 | 44,037 | |||||
| Commitments and contingencies—Note 13 | |||||||
| Shareholders’ equity | |||||||
| Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none | — | — | |||||
| Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 257,395,577 and 256,084,913 | 3 | 3 | |||||
| Additional paid-in capital | 9,536 | 8,547 | |||||
| Retained earnings | 19,988 | 18,054 | |||||
| Accumulated other comprehensive loss | (986 | ) | (101 | ) | |||
| Total shareholders’ equity | 28,541 | 26,503 | |||||
| Total liabilities and shareholders’ equity | $ | 71,571 | $ | 70,540 |
See accompanying notes.
-72-
Anthem, Inc.
Consolidated Statements of Income
| Years Ended December 31 | |||||||||||
| (In millions, except per share data) | 2018 | 2017 | 2016 | ||||||||
| Revenues | |||||||||||
| Premiums | $ | 85,421 | $ | 83,648 | $ | 78,860 | |||||
| Administrative fees and other revenue | 5,920 | 5,413 | 5,334 | ||||||||
| Total operating revenue | 91,341 | 89,061 | 84,194 | ||||||||
| Net investment income | 970 | 867 | 779 | ||||||||
| Net realized (losses) gains on financial instruments | (180 | ) | 145 | 5 | |||||||
| Other-than-temporary impairment losses on investments: | |||||||||||
| Total other-than-temporary impairment losses on investments | (29 | ) | (35 | ) | (147 | ) | |||||
| Portion of other-than-temporary impairment losses recognized in other comprehensive (loss) income | 3 | 2 | 32 | ||||||||
| Other-than-temporary impairment losses recognized in income | (26 | ) | (33 | ) | (115 | ) | |||||
| Total revenues | 92,105 | 90,040 | 84,863 | ||||||||
| Expenses | |||||||||||
| Benefit expense | 71,895 | 72,236 | 66,834 | ||||||||
| Selling, general and administrative expense | 14,020 | 12,650 | 12,559 | ||||||||
| Interest expense | 753 | 739 | 723 | ||||||||
| Amortization of other intangible assets | 358 | 169 | 192 | ||||||||
| Loss on extinguishment of debt | 11 | 282 | — | ||||||||
| Total expenses | 87,037 | 86,076 | 80,308 | ||||||||
| Income before income tax expense | 5,068 | 3,964 | 4,555 | ||||||||
| Income tax expense | 1,318 | 121 | 2,085 | ||||||||
| Net income | $ | 3,750 | $ | 3,843 | $ | 2,470 | |||||
| Net income per share | |||||||||||
| Basic | $ | 14.53 | $ | 14.70 | $ | 9.39 | |||||
| Diluted | $ | 14.19 | $ | 14.35 | $ | 9.21 | |||||
| Dividends per share | $ | 3.00 | $ | 2.70 | $ | 2.60 |
See accompanying notes.
-73-
Anthem, Inc.
Consolidated Statements of Comprehensive Income
| Years Ended December 31 | ||||||||||||
| (In millions) | 2018 | 2017 | 2016 | |||||||||
| Net income | $ | 3,750 | $ | 3,843 | $ | 2,470 | ||||||
| Other comprehensive (loss) income, net of tax: | ||||||||||||
| Change in net unrealized gains/losses on investments | (418 | ) | 173 | 118 | ||||||||
| Change in non-credit component of other-than-temporary impairment losses on investments | (2 | ) | 4 | 5 | ||||||||
| Change in net unrealized gains/losses on cash flow hedges | 37 | (65 | ) | (87 | ) | |||||||
| Change in net periodic pension and postretirement costs | (90 | ) | 51 | (13 | ) | |||||||
| Foreign currency translation adjustments | (1 | ) | 3 | 2 | ||||||||
| Other comprehensive (loss) income | (474 | ) | 166 | 25 | ||||||||
| Total comprehensive income | $ | 3,276 | $ | 4,009 | $ | 2,495 |
See accompanying notes.
-74-
Anthem, Inc.
Consolidated Statements of Cash Flows
| Years Ended December 31 | |||||||||||
| (In millions) | 2018 | 2017 | 2016 | ||||||||
| Operating activities | |||||||||||
| Net income | $ | 3,750 | $ | 3,843 | $ | 2,470 | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net realized losses (gains) on financial instruments | 180 | (145 | ) | (5 | ) | ||||||
| Other-than-temporary impairment losses recognized in income | 26 | 33 | 115 | ||||||||
| Loss on extinguishment of debt | 11 | 282 | — | ||||||||
| Loss on disposal of assets | 8 | 13 | 5 | ||||||||
| Deferred income taxes | 91 | (1,272 | ) | 127 | |||||||
| Amortization, net of accretion | 1,008 | 780 | 808 | ||||||||
| Depreciation expense | 124 | 111 | 104 | ||||||||
| Impairment of property and equipment | 5 | 2 | 45 | ||||||||
| Share-based compensation | 226 | 170 | 165 | ||||||||
| Excess tax benefits from share-based compensation | — | — | (54 | ) | |||||||
| Changes in operating assets and liabilities: | |||||||||||
| Receivables, net | (695 | ) | (22 | ) | (1,381 | ) | |||||
| Other invested assets | (1 | ) | (36 | ) | (19 | ) | |||||
| Other assets | (26 | ) | (629 | ) | (128 | ) | |||||
| Policy liabilities | (1,059 | ) | 732 | 322 | |||||||
| Unearned income | (36 | ) | (120 | ) | (174 | ) | |||||
| Accounts payable and accrued expenses | 122 | 922 | 182 | ||||||||
| Other liabilities | (25 | ) | (120 | ) | 606 | ||||||
| Income taxes | 323 | (194 | ) | 179 | |||||||
| Other, net | (205 | ) | (165 | ) | (97 | ) | |||||
| Net cash provided by operating activities | 3,827 | 4,185 | 3,270 | ||||||||
| Investing activities | |||||||||||
| Purchases of fixed maturity securities | (8,244 | ) | (9,795 | ) | (10,158 | ) | |||||
| Proceeds from fixed maturity securities: | |||||||||||
| Sales | 6,442 | 7,932 | 8,636 | ||||||||
| Maturities, calls and redemptions | 1,938 | 1,848 | 1,419 | ||||||||
| Purchases of equity securities | (896 | ) | (5,416 | ) | (1,476 | ) | |||||
| Proceeds from sales of equity securities | 2,809 | 3,463 | 1,593 | ||||||||
| Purchases of other invested assets | (531 | ) | (1,164 | ) | (433 | ) | |||||
| Proceeds from sales of other invested assets | 411 | 219 | 305 | ||||||||
| Changes in collateral and settlement of non-hedging derivatives | — | 65 | (35 | ) | |||||||
| Changes in securities lending collateral | (149 | ) | 625 | 222 | |||||||
| Purchases of subsidiaries, net of cash acquired | (1,760 | ) | (2,080 | ) | — | ||||||
| Purchases of property and equipment | (1,208 | ) | (800 | ) | (584 | ) | |||||
| Proceeds from sales of property and equipment | — | 9 | — | ||||||||
| Other, net | (71 | ) | 12 | (3 | ) | ||||||
| Net cash used in investing activities | (1,259 | ) | (5,082 | ) | (514 | ) | |||||
| Financing activities | |||||||||||
| Net (repayments of) proceeds from commercial paper borrowings | (107 | ) | 175 | (53 | ) | ||||||
| Proceeds from long-term borrowings | 835 | 5,458 | — | ||||||||
| Repayments of long-term borrowings | (1,684 | ) | (2,815 | ) | — | ||||||
| Proceeds from short-term borrowings | 9,120 | 5,835 | 2,400 | ||||||||
| Repayments of short-term borrowings | (9,250 | ) | (5,000 | ) | (2,500 | ) | |||||
| Changes in securities lending payable | 150 | (625 | ) | (222 | ) | ||||||
| Changes in bank overdrafts | (210 | ) | 71 | 513 | |||||||
| Proceeds from sale of put options | 1 | 1 | — | ||||||||
| Proceeds from issuance of common stock under Equity Units stock purchase contracts | 1,250 | — | — | ||||||||
| Repurchase and retirement of common stock | (1,685 | ) | (1,998 | ) | — | ||||||
| Change in collateral and settlements of debt-related derivatives | 23 | (149 | ) | (360 | ) | ||||||
| Cash dividends | (776 | ) | (705 | ) | (684 | ) | |||||
| Proceeds from issuance of common stock under employee stock plans | 173 | 225 | 120 | ||||||||
| Taxes paid through withholding of common stock under employee stock plans | (81 | ) | (46 | ) | (67 | ) | |||||
| Excess tax benefits from share-based compensation | — | — | 54 | ||||||||
| Net cash (used in) provided by financing activities | (2,241 | ) | 427 | (799 | ) | ||||||
| Effect of foreign exchange rates on cash and cash equivalents | (2 | ) | 4 | 5 | |||||||
| Change in cash and cash equivalents | 325 | (466 | ) | 1,962 | |||||||
| Cash and cash equivalents at beginning of year | 3,609 | 4,075 | 2,113 | ||||||||
| Cash and cash equivalents at end of year | $ | 3,934 | $ | 3,609 | $ | 4,075 |
See accompanying notes.
-75-
Anthem, Inc.
Consolidated Statements of Shareholders’ Equity
| Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Total Shareholders’ Equity | |||||||||||||||||||
| (In millions) | Number of Shares | Par Value | Retained Earnings | |||||||||||||||||||
| January 1, 2016 | 261.2 | $ | 3 | $ | 8,556 | $ | 14,778 | $ | (292 | ) | $ | 23,045 | ||||||||||
| Net income | — | — | — | 2,470 | — | 2,470 | ||||||||||||||||
| Other comprehensive income | — | — | — | — | 25 | 25 | ||||||||||||||||
| Dividends and dividend equivalents | — | — | — | (688 | ) | — | (688 | ) | ||||||||||||||
| Issuance of common stock under employee stock plans, net of related tax benefits | 2.5 | — | 249 | — | — | 249 | ||||||||||||||||
| December 31, 2016 | 263.7 | 3 | 8,805 | 16,560 | (267 | ) | 25,101 | |||||||||||||||
| Net income | — | — | — | 3,843 | — | 3,843 | ||||||||||||||||
| Other comprehensive income | — | — | — | — | 166 | 166 | ||||||||||||||||
| Premiums for and settlement of equity options | — | — | 1 | — | — | 1 | ||||||||||||||||
| Repurchase and retirement of common stock | (10.5 | ) | — | (356 | ) | (1,642 | ) | — | (1,998 | ) | ||||||||||||
| Dividends and dividend equivalents | — | — | — | (707 | ) | — | (707 | ) | ||||||||||||||
| Issuance of common stock under employee stock plans, net of related tax benefits | 2.9 | — | 342 | — | — | 342 | ||||||||||||||||
| Convertible debenture conversions | — | — | (245 | ) | — | — | (245 | ) | ||||||||||||||
| December 31, 2017 | 256.1 | 3 | 8,547 | 18,054 | (101 | ) | 26,503 | |||||||||||||||
| Adoption of Accounting Standards Update No. 2016-01 (Note 2) | — | — | — | 320 | (320 | ) | — | |||||||||||||||
| January 1, 2018 | 256.1 | 3 | 8,547 | 18,374 | (421 | ) | 26,503 | |||||||||||||||
| Net income | — | — | — | 3,750 | — | 3,750 | ||||||||||||||||
| Other comprehensive loss | — | — | — | — | (474 | ) | (474 | ) | ||||||||||||||
| Issuance of common stock under Equity Units stock purchase contracts | 6.0 | — | 1,250 | — | — | 1,250 | ||||||||||||||||
| Premiums for and settlement of equity options | — | — | 1 | — | — | 1 | ||||||||||||||||
| Repurchase and retirement of common stock | (6.8 | ) | — | (243 | ) | (1,442 | ) | — | (1,685 | ) | ||||||||||||
| Dividends and dividend equivalents | — | — | — | (785 | ) | — | (785 | ) | ||||||||||||||
| Issuance of common stock under employee stock plans, net of related tax benefits | 2.1 | — | 318 | — | — | 318 | ||||||||||||||||
| Convertible debenture conversions | — | — | (337 | ) | — | — | (337 | ) | ||||||||||||||
| Adoption of Accounting Standards Update No. 2018-02 (Note 2) | — | — | — | 91 | (91 | ) | — | |||||||||||||||
| December 31, 2018 | 257.4 | $ | 3 | $ | 9,536 | $ | 19,988 | $ | (986 | ) | $ | 28,541 |
See accompanying notes.
-76-
Anthem, Inc.
Notes to Consolidated Financial Statements
December 31, 2018
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
- Organization
References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.
We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 40 medical members through our affiliated health plans as of December 31, 2018. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs; Health Maintenance Organizations, or HMOs; Point-of-Service, or POS, plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans, or CDHPs; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with the Federal Employee Program®, or FEP®.
We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Georgia, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees in Louisiana, South Carolina and western New York. Through our subsidiaries, we also serve customers in over 25 states across the country as America’s 1st Choice, Amerigroup, Aspire Health, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or UniCare. We are licensed to conduct insurance operations in all 50 states and the District of Columbia through our subsidiaries.
- Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying consolidated financial statements include the accounts of Anthem and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles, or GAAP. All significant intercompany accounts and transactions have been eliminated in consolidation.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar, or USD. We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation or adjusted to conform to the current year rounding convention of reporting financial data in whole millions of dollars, except as otherwise noted.
-77-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Use of Estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Cash and Cash Equivalents: Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $222 and $182 at December 31, 2018 and 2017, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: Financial Accounting Standards Board, or FASB, other-than-temporary impairment, or OTTI, guidance applies to fixed maturity securities and provides guidance on the recognition, presentation of, and disclosures for OTTIs. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is presented within the other-than-temporary impairment losses recognized in the income line item on our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, the credit component of the OTTI is presented within the other-than-temporary impairment losses recognized in the income line item on our consolidated statements of income and the non-credit component of the OTTI is recognized in other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an OTTI is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of acquisition. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments are reported within net investment income.
Effective January 1, 2018 and in accordance with the FASB guidance, the changes in fair value of our marketable equity securities are recognized in our results of operations within the net realized gains and losses on financial instruments. Prior to 2018, the unrealized gains or losses on our equity securities previously classified as available-for-sale were included in accumulated other comprehensive loss as a separate component of shareholders’ equity, unless the decline in value was deemed to be other-than-temporary and we did not have the intent and ability to hold such equity securities until their full cost can be recovered, in which case such equity securities were written down to fair value and the loss was charged to other-than-temporary impairment losses recognized in income.
We maintain various rabbi trusts to account for the assets and liabilities under certain deferred compensation plans. Under these plans, the participants can defer certain types of compensation and elect to receive a return on the deferred amounts based on the changes in fair value of various investment options, primarily a variety of mutual funds. We have corporate-owned life insurance policies on certain participants in our deferred compensation plans. The cash surrender value of the corporate-owned life insurance policies is reported in other invested assets, long-term, in the consolidated balance sheets. The remaining rabbi trust assets are generally invested according to the participant’s investment election and are classified as trading, which are reported in other invested assets, current, in the consolidated balance sheets.
-78-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
We use the equity method of accounting for investments in companies in which our ownership interest enables us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. Under FASB guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the collateral as an asset, which is reported as securities lending collateral on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported as securities lending payable. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $278 and $302 at December 31, 2018 and 2017, respectively. Self-funded receivables include administrative fees, claims and other amounts due from self-funded customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $47 and $153 at December 31, 2018 and 2017, respectively. The allowance for doubtful accounts is based on historical collection trends and our judgment regarding the ability to collect specific accounts.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, other government receivables and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $280 and $306 at December 31, 2018 and 2017, respectively, which is based on historical collection trends and our judgment regarding the ability to collect specific accounts.
Income Taxes: We file a consolidated income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact from amounts initially recorded for business combinations, if any, and amounts recorded to accumulated other comprehensive loss. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.
We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.
Property and Equipment: Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from fifteen to thirty-nine years for buildings and improvements, three to five years for computer equipment and software, and the lesser of the remaining life of the building lease, if any, or seven years for furniture and other equipment. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized over five years.
Goodwill and Other Intangible Assets: FASB guidance requires business combinations to be accounted for using the acquisition method of accounting and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair
-79-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses, non-compete and other agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.
Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are tested for impairment separately.
FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used. We began our 2018 annual test with qualitative analyses.
Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors, and entity specific events.
Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry’s weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations include market comparisons to publicly traded companies in our industry and are based on observed multiples of certain measures including revenue; earnings before interest, taxes, depreciation and amortization, or EBITDA; and book value of invested capital. A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset’s fair value. This determination is made at the reporting unit level and consists of two steps. First, the fair value of a reporting unit is determined and compared to its carrying amount. Second, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation on a business acquisition, at the impairment test date.
Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.
Derivative Financial Instruments: We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.
We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing
-80-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.
All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, as well as the ineffective portion of the gain or loss, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.
From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.
Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December 31, 2018, we believe there were no material concentrations of credit risk with any individual counterparty.
We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty.
Retirement Benefits: We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with current and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.
We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.
The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date. At the December 31, 2017 measurement date, we changed the discount rate setting methodology from the single equivalent discount rate to the annual spot rate approach. Under the spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan’s cash flows to determine the plan’s obligations. The spot rate approach produces a more precise measure of service and interest cost, and results in obligations that are equal at the measurement date under both methods.
The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost trend rate declining to an ultimate healthcare cost trend rate over a select number of years.
-81-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Medical Claims Payable: Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2) claims reported to us and processed through our systems but not yet paid.
Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the claim liabilities be appropriate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into “claim triangles,” which compare claim incurred dates to the dates of claim payments. This information is analyzed to create “completion factors” that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.
For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend levels, or “trend factors.”
We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income statement and financial position could be impacted in future periods.
Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December 31, 2018 or 2017.
Benefit expense includes incurred medical claims as well as quality improvement expenses for our fully-insured members. Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members.
Reserves for Future Policy Benefits: Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.
The current portion of reserves for future policy benefits relates to the portion of such reserves that we expect to pay within one year. We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.
Other Policyholder Liabilities: Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves. Other policyholder liabilities also includes liabilities for premium refunds based upon the minimum medical loss ratio, or MLR, the relative health risk of members, or other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what
-82-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our customers and can vary from period to period based on the specific contractual requirements.
We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended, or collectively, the ACA. If we do not meet or exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by subsidiary, state and applicable line of business (Large Group, Small Group, Individual and Medicare) in accordance with regulations issued by the Department of Health and Human Services, or HHS. Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.
We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our GAAP basis consolidated financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.
Revenue Recognition: Premiums for fully-insured contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of amounts recognized for the ACA MLR rebates, risk adjustment, reinsurance and risk corridor or contractual premium stabilization programs. Premium payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted government agencies require that we defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized.
Administrative fees and other revenues include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion of their claims experience. We charge these self-funded groups an administrative fee, which is based on the number of members in a group or the group’s claim experience. In addition, administrative fees and other revenues include amounts received for the administration of Medicare or certain other government programs. Under our self-funded arrangements, revenue is recognized as administrative services are performed. All benefit payments under these programs are excluded from benefit expense.
For our non-fully-insured contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at December 31, 2018. Revenue recognized in 2018 from performance obligations related to prior years, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Share-Based Compensation: Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share which is 95% of the fair value of a share of common stock on the last trading day of the plan quarter. The employee stock purchase plan discount is not recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in the income statement based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax benefits in the income statement. Our
-83-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
share-based employee compensation plans and assumptions are described in Note 14, “Capital Stock.” Also see “Recently Adopted Accounting Guidance” within this Note 2 for reference to accounting changes adopted related to share-based compensation.
Advertising and Marketing Costs: We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Local Group customers with a smaller employee base. Products for National Accounts and Local Group customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer and working with industry specialists from our in-house sales force. In the Individual and Small Group markets we offer products through state or federally facilitated marketplaces, or public exchanges, and off-exchange products. The cost of advertising and marketing for product promotion is expensed as incurred while advertising and marketing costs associated with our corporate image is expensed when first aired. Total advertising and marketing expense was $385, $338 and $246 for the years ended December 31, 2018, 2017 and 2016, respectively.
Health Insurance Provider Fee: The ACA imposed an annual Health Insurance Provider Fee, or HIP Fee, on health insurers that write certain types of health insurance on U.S. risks. The annual HIP Fee is allocated to health insurers based on the ratio of the amount of an insurer’s net premium revenues written during the preceding calendar year to the amount of health insurance premium for all U.S. health risk for those certain lines of business written during the preceding calendar year. We record our estimated liability for the HIP Fee in full at the beginning of the year with a corresponding deferred asset that is amortized on a straight-line basis to selling, general and administrative expense. The final calculation and payment of the annual HIP Fee is due by September 30th of each fee year. The HIP Fee is non-deductible for federal income tax purposes. We price our affected products to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee. The total amount due from allocations to health insurers was $11,300 for 2016, was suspended for 2017, had resumed and increased to $14,300 for 2018 and is suspended for 2019. The HIP Fee is scheduled to go back into effect for 2020. For the years ended December 31, 2018 and 2016, we recognized $1,544 and $1,176, respectively, as selling, general and administrative expense related to the HIP Fee. There was no corresponding expense for 2017 due to the suspension of the HIP Fee for 2017.
Earnings per Share: Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.
Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share may include the dilutive effect of stock options, restricted stock, convertible debentures and Equity Units, using the treasury stock method. See Note 12, “Debt,” for a description of our Equity Units. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.
Recently Adopted Accounting Guidance: In February 2018, the FASB issued Accounting Standards Update No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, or ASU 2018-02. On December 22, 2017, the federal government enacted a tax bill, H.R.1, An act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018, or the Tax Cuts and Jobs Act. The Tax Cuts and Jobs Act contains significant changes to corporate taxation, including, but not limited to, reducing the U.S. federal corporate income tax rate from 35% to 21% and modifying or limiting many business deductions. Current FASB guidance requires adjustments of deferred taxes due to a change in the federal corporate income tax rate to be included in income from operations. As a result, the tax effects of items within accumulated other comprehensive loss did not reflect the appropriate tax rate. The amendments in ASU 2018-02 allow a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the change in the federal corporate income tax rate. We adopted the amendments in ASU 2018-02 for our interim and annual reporting periods beginning on January 1, 2018 and reclassified $91 of stranded tax effects from accumulated other comprehensive loss to retained earnings on our consolidated balance sheets. The adoption of ASU 2018-02 did not have any impact on our results of operations or cash flows.
-84-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, or ASU 2017-12. This update amends the hedge accounting recognition and presentation requirements in Topic 815 with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The update also makes certain targeted improvements to simplify the application of the hedge accounting guidance and provides several transition elections. We adopted ASU 2017-12 on October 1, 2017. The adoption of ASU 2017-12 did not have a material impact on our consolidated financial position, results of operations or cash flows.
In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, or ASU 2017-09. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. We adopted ASU 2017-09 on January 1, 2018. The guidance has been and will be applied prospectively to awards modified on or after the adoption date. The adoption of ASU 2017-09 did not have any impact on our consolidated financial position, results of operations or cash flows.
In March 2017, the FASB issued Accounting Standards Update No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, or ASU 2017-07. This amendment requires entities to disaggregate the service cost component from the other components of the benefit cost and present the service cost component in the same income statement line item as other employee compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. Certain of our defined benefit plans have previously been frozen, resulting in no annual service costs, and the remaining service costs for our non-frozen plan are not material. We adopted ASU 2017-07 on January 1, 2018 and it did not have a material impact on our results of operations, cash flows or consolidated financial position.
In December 2016, the FASB issued Accounting Standards Update No. 2016-20, Technical Corrections and
Improvements to Topic 606, Revenue from Contracts with Customers. In May 2016, the FASB issued Accounting Standards Update No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. In April 2016, the FASB issued Accounting Standards Update No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, or ASU 2016-10. In March 2016, the FASB issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross verses Net). These updates provide additional clarification and implementation guidance on the previously issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). Collectively, these updates require a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These updates supersede almost all existing revenue recognition guidance under GAAP, with certain exceptions, including an exception for our premium revenues, which are recorded on the Premiums line item on our consolidated statements of income and will continue to be accounted for in accordance with the provisions of Accounting Standards Codification, or ASC, Topic 944, Financial Services - Insurance. Our administrative service and other contracts that are subject to these Accounting Standards Updates are recorded in the Administrative fees and other revenue line item on our consolidated statements of income and represents approximately 6% of our consolidated total operating revenue. We adopted these standards on January 1, 2018 using the modified retrospective approach. The adoption of these standards did not have a material impact on our beginning retained earnings, results of operations, cash flows or consolidated financial position.
In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, or ASU 2016-18. This update amends ASC Topic 230 to add and clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The guidance requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 using a retrospective approach. The adoption of ASU 2016-18 did not have a material impact on our consolidated statements of cash flows and did not impact our results of operations or consolidated financial position.
In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, or ASU 2016-15. This update addresses the presentation and classification on the statement of cash flows for eight specific items, with the objective of reducing existing diversity in
-85-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
practice in how certain cash receipts and cash payments are presented and classified. We adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on our consolidated statements of cash flows, results of operations or consolidated financial position.
In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, or ASU 2016-09. The amendments in this update simplify several aspects of accounting for and reporting on share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We adopted the amendments in ASU 2016-09 on January 1, 2017. We continue to estimate forfeitures expected to occur in determining stock compensation recognized in each period. We prospectively recognized tax benefits of $36, or $0.13 per diluted share, for the year ended December 31, 2017 in our consolidated statements of income, which previously would have been recorded to additional paid-in capital. In addition, we prospectively recognized excess tax benefits as an operating activity within our consolidated statement of cash flows for the year ended December 31, 2017. Finally, we retrospectively recognized taxes paid on our employees’ behalf through the withholding of common stock as a financing activity within our consolidated statements of cash flows for the years ended December 31, 2017 and 2016.
In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, or ASU 2016-01. The amendments in ASU 2016-01 change the accounting for non-consolidated equity investments that are not accounted for under the equity method of accounting by requiring changes in fair value to be recognized in income. Additionally, ASU 2016-01 simplifies the impairment assessment of equity investments without readily determinable fair values; requires entities to use the exit price when estimating the fair value of financial instruments; and modifies various presentation disclosure requirements for financial instruments. We adopted ASU 2016-01 on January 1, 2018 as a cumulative-effect adjustment and reclassified $320 of unrealized gains on equity investments, net of tax, from accumulated other comprehensive loss to retained earnings on our consolidated balance sheet. Effective January 1, 2018, our results of operations include the changes in fair value of these financial instruments.
In April 2015, the FASB issued Accounting Standards Update No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement, or ASU 2015-05. This update provides guidance to help entities determine whether a cloud computing arrangement contains a software license that should be accounted for as internal-use software or as a service contract. ASU 2015-05 became effective January 1, 2016 and we elected to adopt the provisions of the new guidance prospectively to all arrangements entered into or materially modified on or after January 1, 2016. The adoption of ASU 2015-05 did not have an impact on our consolidated financial position, results of operations or cash flows.
In February 2015, the FASB issued Accounting Standards Update No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, or ASU 2015-02. This update amended the consolidation guidance by modifying the evaluation criteria for whether limited partnerships and similar legal entities are variable interest entities or voting interest entities, eliminating the presumption that a general partner should consolidate a limited partnership, and affecting the consolidation analysis of reporting entities that are involved with variable interest entities. We adopted the provisions of ASU 2015-02 effective January 1, 2016, and re-evaluated all legal entity investments under the revised consolidation model. The adoption of ASU 2015-02 did not have a material impact on our consolidated financial position, results of operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: In November 2018, the FASB issued Accounting Standards Update No. 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, or ASU 2018-19. The amendments in ASU 2018-19 provide additional clarification and implementation guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, or ASU 2016-13, and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 introduces a current expected credit loss model for measuring expected credit losses for certain types of financial instruments held at the reporting date based on historical experience, current conditions and reasonable supportable forecasts. ASU 2016-13 replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities and provides for additional disclosure requirements. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for
-86-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
interim and annual reporting periods beginning after December 15, 2018. We are currently evaluating the effects the adoption of ASU 2016-13 will have on our consolidated financial statements, results of operations and cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract, or ASU 2018-15. The amendments in ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and statement of cash flows. ASU 2018-15 is effective for us on January 1, 2020, with early adoption permitted. The guidance can be applied either prospectively to all implementation costs incurred after the date of adoption or retrospectively. We are currently evaluating the effects the adoption of ASU 2018-15 will have on our consolidated financial position, results of operations and cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, or ASU 2018-14. The amendments in ASU 2018-14 eliminate, add and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.
In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add and modify certain disclosure requirements for fair value measurements. The amendments are effective for our interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for either the entire ASU or only the provisions that eliminate or modify disclosure requirements. We early adopted the provisions that eliminate and modify disclosure requirements on a retrospective basis effective in this Annual Report on Form 10-K and we adopted the new disclosure requirements on a prospective basis effective January 1, 2019.
In August 2018, the FASB issued Accounting Standards Update No. 2018-12, Financial Services Insurance (Topic
944): Targeted Improvements to the Accounting for Long-Duration Contracts, or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2020. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.
In July 2018, the FASB issued Accounting Standards Update No. 2018-11, Leases (Topic 842): Targeted Improvements, or ASU 2018-11, and Accounting Standards Update No. 2018-10, Codification Improvements to Topic 842, Leases, or ASU 2018-10. The amendments in ASU 2018-11 provide for an additional and optional transition method that allows an entity to initially apply ASC Topic 842 at the adoption date and recognize a cumulative effect adjustment to its opening balance of retained earnings in the period of adoption and continue its reporting for the comparative periods presented in accordance with the current lease guidance in ASC Topic 840. The amendments in ASU 2018-11 also provide lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if the nonlease components otherwise would be accounted for under the new revenue guidance in ASC Topic 606 and if certain conditions are met. The amendments in ASU 2018-10
-87-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
provide additional clarification and implementation guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-02, Leases (Topic 842), or ASU 2016-02, and have the same effective and transition requirements as ASU 2016-02. Upon the effective date, ASU 2016-02 will supersede the current lease guidance in ASC Topic 840. Under the new guidance, lessees will be required to recognize for all leases, with the exception of short-term leases, a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis. Concurrently, lessees will be required to recognize a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 became effective for us on January 1, 2019. ASU 2016-02 requires a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative periods presented in the financial statements. As noted above, ASU 2018-11 provides for an additional and optional transition method. We applied the optional transition method upon adoption and have elected the package of practical expedients permitted, which among other things, allows us to carry forward lease classification for our existing leases. In preparation for the adoption of this standard and to enable the preparation of the required financial information, we implemented a new lease accounting software solution as well as new internal controls. The adoption of this standard impacted our consolidated balance sheet in January 2019, as we recorded lease assets and liabilities of approximately $700 for our operating leases. The adoption of this standard did not have an impact on our consolidated statements of income or cash flows. We also do not believe the new standard will have an impact on our liquidity or debt-covenant compliance under our current agreements.
In March 2017, the FASB issued Accounting Standards Update No. 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities, or ASU 2017-08. This update changes the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. Under current guidance, the premium is generally amortized over the contractual life of the instrument. The amendments are to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We adopted ASU 2017-08 on January 1, 2019 and the adoption of this standard did not have a material impact on our beginning retained earnings or upon our consolidated financial position, results of operations or cash flows.
In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, or ASU 2017-04. This update removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. Upon adoption, the guidance is to be applied prospectively. ASU 2017-04 is effective for us on January 1, 2020, with early adoption permitted. The adoption of ASU 2017-04 is not expected to have a material impact on our consolidated financial position, results of operations or cash flows.
There were no other new accounting pronouncements that were issued or became effective during the year ended December 31, 2018 that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.
- Business Acquisitions
Acquisition of America’s 1st Choice
On February 15, 2018, we completed our acquisition of Freedom Health, Inc., Optimum HealthCare, Inc., America’s 1st Choice of South Carolina, Inc. and related entities, or collectively, America’s 1st Choice, a Medicare Advantage organization that offers HMO products, including Chronic Special Needs Plans and Dual-Eligible Special Needs Plans under its Freedom Health and Optimum HealthCare brands in Florida and its America’s 1st Choice of South Carolina brand in South Carolina. At the time of acquisition, through its Medicare Advantage Plans, America’s 1st Choice served approximately one hundred and thirty-five thousand members in twenty-five Florida and three South Carolina counties. This acquisition aligns with our plans for continued growth in the Medicare Advantage and Special Needs populations.
In accordance with FASB accounting guidance for business combinations, the consideration transferred was allocated to the fair value of America’s 1st Choice’s assets acquired and liabilities assumed, including identifiable intangible assets. The excess of the consideration transferred over the fair value of net assets acquired resulted in goodwill of $1,029 at December 31, 2018, of which $295 was tax deductible. All of the goodwill was allocated to our Government Business segment.
-88-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Goodwill recognized from the acquisition of America’s 1st Choice primarily relates to the future economic benefits arising from the assets acquired and is consistent with our stated intentions to strengthen our position and expand operations in the government sector to service Medicare Advantage and Special Needs populations.
The fair value of the net assets acquired from America’s 1st Choice includes $711 of other intangible assets at December 31, 2018, which primarily consist of finite-lived customer relationships with amortization periods ranging from 7 to 13 years. The results of operations of America’s 1st Choice are included in our consolidated financial statements within our Government Business segment for the periods following February 15, 2018. The pro forma effects of this acquisition for prior periods were not material to our consolidated results of operations.
Acquisition of HealthSun
On December 21, 2017, we completed our acquisition of HealthSun Health Plans, Inc., or HealthSun, which at the time of acquisition served approximately forty thousand members in the state of Florida through its Medicare Advantage Plans, and which received a five-star rating from the Centers for Medicare & Medicaid Services. This acquisition aligns with our plans for continued growth in the Medicare Advantage and dual-eligible populations.
In accordance with FASB accounting guidance for business combinations, the consideration transferred was allocated to the fair value of HealthSun’s assets acquired and liabilities assumed, including identifiable intangible assets. The excess of the consideration transferred over the fair value of net assets acquired resulted in goodwill of $1,631, at December 31, 2018, of which $956 was tax deductible. All of the goodwill was allocated to our Government Business segment. Goodwill recognized from the acquisition of HealthSun primarily relates to the future economic benefits arising from the assets acquired and is consistent with our stated intentions to strengthen our position and expand operations in the government sector to service Medicare Advantage and dual-eligible enrollees. Subsequent to the acquisition date, we recognized a $12 decrease to goodwill primarily related to adjustments to provisional amounts of intangible assets recorded on the acquisition date.
The fair value of the net assets acquired from HealthSun includes $637 of other intangible assets at December 31, 2018, which primarily consist of finite-lived customer relationships with amortization periods ranging from 7 to 11 years. The results of operations of HealthSun are included in our consolidated financial statements within our Government Business segment for the periods following December 21, 2017. The pro forma effects of this acquisition for prior periods were not material to our consolidated results of operations.
Termination of Agreement and Plan of Merger with Cigna Corporation
On July 24, 2015, we and Cigna Corporation, or Cigna, announced that we entered into an Agreement and Plan of Merger, or Cigna Merger Agreement, dated as of July 23, 2015, to acquire all outstanding shares of Cigna. On May 12, 2017, we delivered to Cigna a notice terminating the Cigna Merger Agreement. Both we and Cigna have commenced litigation against the other seeking various actions and damages, including Cigna’s damage claim for a $1,850 termination fee pursuant to the terms of the Cigna Merger Agreement. For additional information, see Note 13, “Commitments and Contingencies - Litigation and Regulatory Proceedings - Cigna Corporation Merger Litigation.”
-89-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
- Investments
A summary of current and long-term fixed maturity securities, available-for-sale, at December 31, 2018 and 2017 is as follows:
| Non-Credit Component of OTTIs Recognized in Accumulated Other Comprehensive Loss | |||||||||||||||||||||||
| Cost or Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | ||||||||||||||||||||
| Less than 12 Months | 12 Months or Greater | ||||||||||||||||||||||
| December 31, 2018 | |||||||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||||
| United States Government securities | $ | 414 | $ | 3 | $ | — | $ | (1 | ) | $ | 416 | $ | — | ||||||||||
| Government sponsored securities | 108 | 1 | — | (1 | ) | 108 | — | ||||||||||||||||
| States, municipalities and political subdivisions, tax-exempt | 4,716 | 91 | (3 | ) | (19 | ) | 4,785 | — | |||||||||||||||
| Corporate securities | 8,189 | 33 | (170 | ) | (115 | ) | 7,937 | (3 | ) | ||||||||||||||
| Residential mortgage-backed securities | 2,769 | 31 | (3 | ) | (47 | ) | 2,750 | — | |||||||||||||||
| Commercial mortgage-backed securities | 69 | — | — | (2 | ) | 67 | — | ||||||||||||||||
| Other securities | 1,115 | 14 | (8 | ) | (5 | ) | 1,116 | — | |||||||||||||||
| Total fixed maturity securities | $ | 17,380 | $ | 173 | $ | (184 | ) | $ | (190 | ) | $ | 17,179 | $ | (3 | ) | ||||||||
| December 31, 2017 | |||||||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||||
| United States Government securities | $ | 649 | $ | 2 | $ | (5 | ) | $ | (1 | ) | $ | 645 | $ | — | |||||||||
| Government sponsored securities | 90 | — | — | — | 90 | — | |||||||||||||||||
| States, municipalities and political subdivisions, tax-exempt | 5,854 | 193 | (5 | ) | (7 | ) | 6,035 | — | |||||||||||||||
| Corporate securities | 7,363 | 166 | (30 | ) | (13 | ) | 7,486 | — | |||||||||||||||
| Residential mortgage-backed securities | 2,520 | 39 | (8 | ) | (12 | ) | 2,539 | — | |||||||||||||||
| Commercial mortgage-backed securities | 80 | 1 | — | (2 | ) | 79 | — | ||||||||||||||||
| Other securities | 1,054 | 14 | (3 | ) | (1 | ) | 1,064 | — | |||||||||||||||
| Total fixed maturity securities | $ | 17,610 | $ | 415 | $ | (51 | ) | $ | (36 | ) | $ | 17,938 | $ | — |
-90-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
For fixed maturity securities in an unrealized loss position at December 31, 2018 and 2017, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position.
| Less than 12 Months | 12 Months or Greater | ||||||||||||||||||||
| Number of Securities | Estimated Fair Value | Gross Unrealized Loss | Number of Securities | Estimated Fair Value | Gross Unrealized Loss | ||||||||||||||||
| (Securities are whole amounts) | |||||||||||||||||||||
| December 31, 2018 | |||||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||
| United States Government securities | 5 | $ | 47 | $ | — | 25 | $ | 79 | $ | (1 | ) | ||||||||||
| Government sponsored securities | 8 | 11 | — | 24 | 31 | (1 | ) | ||||||||||||||
| States, municipalities and political subdivisions, tax-exempt | 177 | 295 | (3 | ) | 604 | 1,032 | (19 | ) | |||||||||||||
| Corporate securities | 2,185 | 4,503 | (170 | ) | 1,220 | 2,072 | (115 | ) | |||||||||||||
| Residential mortgage-backed securities | 259 | 383 | (3 | ) | 816 | 1,458 | (47 | ) | |||||||||||||
| Commercial mortgage-backed securities | 6 | 11 | — | 19 | 37 | (2 | ) | ||||||||||||||
| Other securities | 193 | 599 | (8 | ) | 93 | 237 | (5 | ) | |||||||||||||
| Total fixed maturity securities | 2,833 | $ | 5,849 | $ | (184 | ) | 2,801 | $ | 4,946 | $ | (190 | ) | |||||||||
| December 31, 2017 | |||||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||
| United States Government securities | 36 | $ | 450 | $ | (5 | ) | 11 | $ | 56 | $ | (1 | ) | |||||||||
| Government sponsored securities | 12 | 16 | — | 16 | 15 | — | |||||||||||||||
| States, municipalities and political subdivisions, tax-exempt | 414 | 641 | (5 | ) | 189 | 356 | (7 | ) | |||||||||||||
| Corporate securities | 1,081 | 2,200 | (30 | ) | 279 | 330 | (13 | ) | |||||||||||||
| Residential mortgage-backed securities | 445 | 1,050 | (8 | ) | 287 | 478 | (12 | ) | |||||||||||||
| Commercial mortgage-backed securities | 7 | 14 | — | 12 | 27 | (2 | ) | ||||||||||||||
| Other securities | 132 | 406 | (3 | ) | 20 | 36 | (1 | ) | |||||||||||||
| Total fixed maturity securities | 2,127 | $ | 4,777 | $ | (51 | ) | 814 | $ | 1,298 | $ | (36 | ) |
The amortized cost and fair value of fixed maturity securities at December 31, 2018, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
| Amortized Cost | Estimated Fair Value | ||||||
| Due in one year or less | $ | 543 | $ | 544 | |||
| Due after one year through five years | 5,174 | 5,105 | |||||
| Due after five years through ten years | 4,956 | 4,857 | |||||
| Due after ten years | 3,869 | 3,856 | |||||
| Mortgage-backed securities | 2,838 | 2,817 | |||||
| Total fixed maturity securities | $ | 17,380 | $ | 17,179 |
-91-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Equity Securities
A summary of current and long-term marketable equity securities at December 31, 2018 and 2017 is as follows:
| December 31, 2018 | December 31, 2017 | ||||||
| Equity Securities: | |||||||
| Exchange traded funds | $ | 2 | $ | 1,300 | |||
| Fixed maturity mutual funds | 557 | 791 | |||||
| Common equity securities | 654 | 1,254 | |||||
| Private equity securities | 313 | 287 | |||||
| Total | $ | 1,526 | $ | 3,632 |
Investment Income
The major categories of net investment income for the years ended December 31, 2018, 2017 and 2016 are as follows:
| 2018 | 2017 | 2016 | |||||||||
| Fixed maturity securities | $ | 681 | $ | 614 | $ | 673 | |||||
| Equity securities | 86 | 116 | 62 | ||||||||
| Cash equivalents | 51 | 25 | 3 | ||||||||
| Other | 193 | 153 | 85 | ||||||||
| Investment income | 1,011 | 908 | 823 | ||||||||
| Investment expense | (41 | ) | (41 | ) | (44 | ) | |||||
| Net investment income | $ | 970 | $ | 867 | $ | 779 |
-92-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Investment Gains
Net realized investment gains/losses and the net change in unrealized appreciation/depreciation on investments for the years ended December 31, 2018, 2017 and 2016 are as follows:
| 2018 | 2017 | 2016 | |||||||||
| Net realized gains (losses): | |||||||||||
| Fixed maturity securities: | |||||||||||
| Gross realized gains from sales | $ | 85 | $ | 137 | $ | 210 | |||||
| Gross realized losses from sales | (116 | ) | (55 | ) | (152 | ) | |||||
| Net realized (losses) gains from sales of fixed maturity securities | (31 | ) | 82 | 58 | |||||||
| Equity securities: | |||||||||||
| Gross realized gains | 77 | 140 | 205 | ||||||||
| Gross realized losses | (276 | ) | (17 | ) | (50 | ) | |||||
| Net realized (losses) gains on equity securities | (199 | ) | 123 | 155 | |||||||
| Other investments: | |||||||||||
| Gross realized gains from sales | 27 | — | 7 | ||||||||
| Gross realized losses from sales | — | (5 | ) | — | |||||||
| Net realized gains (losses) from sales of other investments | 27 | (5 | ) | 7 | |||||||
| Net realized (losses) gains on investments | (203 | ) | 200 | 220 | |||||||
| Other-than-temporary impairment losses recognized in income: | |||||||||||
| Fixed maturity securities | (9 | ) | (4 | ) | (75 | ) | |||||
| Equity securities | — | (15 | ) | (22 | ) | ||||||
| Other investments | (17 | ) | (14 | ) | (18 | ) | |||||
| Other-than-temporary impairment losses recognized in income | (26 | ) | (33 | ) | (115 | ) | |||||
| Change in net unrealized (losses) gains on investments: | |||||||||||
| Fixed maturity securities | (529 | ) | 156 | 193 | |||||||
| Equity securities | — | 111 | 7 | ||||||||
| Other investments | 5 | (10 | ) | (2 | ) | ||||||
| Total change in net unrealized (losses) gains on investments | (524 | ) | 257 | 198 | |||||||
| Deferred income tax benefit (expense) | 106 | (84 | ) | (80 | ) | ||||||
| Change in net unrealized (losses) gains on investments | (418 | ) | 173 | 118 | |||||||
| Net realized (losses) gains on investments, other-than-temporary impairment losses recognized in income and change in net unrealized (losses) gains on investments | $ | (647 | ) | $ | 340 | $ | 223 |
The gains and losses related to equity securities for the year ended December 31, 2018 are as follows:
| 2018 | |||
| Net realized losses recognized on equity securities | $ | (199 | ) |
| Less: Net realized losses recognized on equity securities sold during the period | 57 | ||
| Unrealized losses recognized in income on equity securities still held at December 31 | $ | (142 | ) |
-93-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
Proceeds from sales, maturities, calls or redemptions of fixed maturity securities and the related gross realized gains and gross realized losses for the years ended December 31 are as follows:
| 2018 | 2017 | 2016 | |||||||||
| Proceeds | $ | 8,380 | $ | 9,780 | $ | 10,055 | |||||
| Gross realized gains | 85 | 137 | 210 | ||||||||
| Gross realized losses | (116 | ) | (55 | ) | (152 | ) |
A significant judgment in the valuation of investments is the determination of when an other-than-temporary decline in value has occurred. We follow a consistent and systematic process for recognizing impairments on securities that sustain other-than-temporary declines in value. We have established a committee responsible for the impairment review process. The decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors including, but not limited to: (i) the length of time and the extent to which the fair value has been less than book value, (ii) the financial condition and near term prospects of the issuer, (iii) our intent and ability to retain impaired investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv) our intent to sell or the likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v) whether the debtor is current on interest and principal payments, (vi) the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors) and (vii) general market conditions and industry or sector specific factors. For securities that are deemed to be other-than-temporarily impaired, the security is adjusted to fair value and the resulting losses are recognized in the consolidated statements of income. The new cost basis of the impaired securities is not increased for future recoveries in fair value.
Other-than-temporary impairments recorded in 2018, 2017 and 2016 were primarily the result of the continued credit deterioration on specific issuers in the bond markets. There were no individually significant OTTI losses on investments by issuer during 2018, 2017 or 2016.
Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have an adverse material impact on our results of operations or shareholders’ equity.
The changes in the amount of the credit component of OTTI losses on fixed maturity securities recognized in income, for which a portion of the OTTI losses was recognized in other comprehensive income, was not material for the years ended December 31, 2018, 2017 or 2016.
At December 31, 2018 and 2017, no investments exceeded 10% of shareholders’ equity.
At December 31, 2018 and 2017, the carrying value of fixed maturity investments that did not produce income during the years then ended were $0 and $9, respectively.
As of December 31, 2018 and 2017, we had committed approximately $873 and $824, respectively, to future capital calls from various third-party investments in exchange for an ownership interest in the related entities.
At December 31, 2018 and 2017, securities with carrying values of approximately $487 and $561, respectively, were deposited by our insurance subsidiaries under requirements of regulatory authorities.
-94-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Securities Lending Programs
The fair value of the collateral received at the time of the securities lending transactions amounted to $604 and $454 at December 31, 2018 and 2017, respectively. The value of the collateral represented 102% and 104% of the market value of the securities on loan at December 31, 2018 and 2017, respectively.
The remaining contractual maturity of our securities lending agreements at December 31, 2018 is as follows:
| Overnight and Continuous | Less than 30 days | 30-90 days | Greater Than 90 days | Total | |||||||||||||||
| Securities lending transactions | |||||||||||||||||||
| United States Government securities | $ | 169 | $ | — | $ | — | $ | — | $ | 169 | |||||||||
| Corporate securities | 396 | — | — | — | 396 | ||||||||||||||
| Equity securities | 39 | — | — | — | 39 | ||||||||||||||
| Total | $ | 604 | $ | — | $ | — | $ | — | $ | 604 |
-95-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
- Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements which reduce credit risk by permitting net settlement of transactions. We had posted collateral of $1 and $12 related to our derivative financial instruments at December 31, 2018 and 2017, respectively.
A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December 31, 2018 and 2017 is as follows:
| Contractual/ Notional Amount | Balance Sheet Location | Estimated Fair Value | |||||||||||
| Asset | (Liability) | ||||||||||||
| December 31, 2018 | |||||||||||||
| Hedging instruments | |||||||||||||
| Interest rate swaps - fixed to floating | $ | 1,200 | Other assets/other liabilities | $ | 7 | $ | (11 | ) | |||||
| Non-hedging instruments | |||||||||||||
| Interest rate swaps | 164 | Equity securities | 4 | (1 | ) | ||||||||
| Options | 100 | Other assets/other liabilities | — | — | |||||||||
| Futures | 415 | Equity securities | 5 | (5 | ) | ||||||||
| Subtotal non-hedging | 679 | Subtotal non-hedging | 9 | (6 | ) | ||||||||
| Total derivatives | $ | 1,879 | Total derivatives | 16 | (17 | ) | |||||||
| Amounts netted | (14 | ) | 14 | ||||||||||
| Net derivatives | $ | 2 | $ | (3 | ) | ||||||||
| December 31, 2017 | |||||||||||||
| Hedging instruments | |||||||||||||
| Interest rate swaps - fixed to floating | $ | 1,235 | Other assets/other liabilities | $ | 2 | $ | (5 | ) | |||||
| Interest rate swaps - forward starting pay fixed | 425 | Other assets/other liabilities | — | $ | (9 | ) | |||||||
| Subtotal hedging | 1,660 | Subtotal hedging | 2 | (14 | ) | ||||||||
| Non-hedging instruments | |||||||||||||
| Interest rate swaps | 171 | Equity securities | 1 | (5 | ) | ||||||||
| Options | 100 | Other assets/other liabilities | — | — | |||||||||
| Futures | 117 | Equity securities | — | (2 | ) | ||||||||
| Subtotal non-hedging | 388 | Subtotal non-hedging | 1 | (7 | ) | ||||||||
| Total derivatives | $ | 2,048 | Total derivatives | 3 | (21 | ) | |||||||
| Amounts netted | (1 | ) | 1 | ||||||||||
| Net derivatives | $ | 2 | $ | (20 | ) |
-96-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Fair Value Hedges
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the London Interbank Offered Rate, or LIBOR. A summary of our outstanding fair value hedges at December 31, 2018 and 2017 is as follows:
| Type of Fair Value Hedges | Year Entered Into | Outstanding Notional Amount | Interest Rate Received | Expiration Date | |||||||||||
| 2018 | 2017 | ||||||||||||||
| Interest rate swap | 2018 | $ | 50 | $ | — | 4.101 | % | September 1, 2027 | |||||||
| Interest rate swap | 2018 | 450 | — | 3.300 | January 15, 2023 | ||||||||||
| Interest rate swap | 2018 | 90 | — | 4.350 | August 15, 2020 | ||||||||||
| Interest rate swap | 2017 | 50 | 50 | 4.350 | August 15, 2020 | ||||||||||
| Interest rate swap | 2015 | 200 | 200 | 4.350 | August 15, 2020 | ||||||||||
| Interest rate swap | 2014 | 150 | 150 | 4.350 | August 15, 2020 | ||||||||||
| Interest rate swap | 2013 | 10 | 10 | 4.350 | August 15, 2020 | ||||||||||
| Interest rate swap | 2012 | 200 | 200 | 4.350 | August 15, 2020 | ||||||||||
| Interest rate swap | 2012 | — | 625 | 1.875 | January 15, 2018 | ||||||||||
| Total notional amount outstanding | $ | 1,200 | $ | 1,235 |
The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December 31, 2018 and 2017:
| Balance Sheet Classification in Which Hedged Item is Included | Carrying Amount of Hedged Liability | Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Current portion of long term-debt | $ | 849 | $ | 1,275 | $ | 7 | $ | 2 | ||||||||
| Long-term debt | 17,217 | 17,382 | (11 | ) | (5 | ) |
Cash Flow Hedges
We have entered into a series of forward starting pay fixed interest rate swaps with the objective of eliminating the variability of cash flows in the interest payments on anticipated future financings. During 2018, swaps in the notional amount of $425 were terminated. We received an aggregate of $24 from the swap counter parties upon termination.
The unrecognized loss for all outstanding, expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $246 and $233 at December 31, 2018 and 2017, respectively. As of December 31, 2018, the total amount of amortization over the next twelve months for all cash flow hedges is estimated to increase interest expense by approximately $14. No amounts were excluded from effectiveness testing.
-97-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of the effect of cash flow hedges in accumulated other comprehensive loss for the years ended December 31, 2018 and 2017 is as follows:
| Hedge Loss Recognized in Other Comprehensive Income (Loss) | Income Statement Location of Loss Reclassification from Accumulated Other Comprehensive Loss | Hedge Loss Reclassified from Accumulated Other Comprehensive Loss | ||||||||
| Type of Cash Flow Hedge | ||||||||||
| Year ended December 31, 2018 | ||||||||||
| Forward starting pay fixed swaps | $ | (33 | ) | Interest expense | $ | (14 | ) | |||
| Year ended December 31, 2017 | ||||||||||
| Forward starting pay fixed swaps | $ | (112 | ) | Interest expense | $ | (7 | ) | |||
| Forward starting pay fixed swaps | Net realized (losses) gains on financial instruments | $ | (7 | ) |
A summary of the effect of cash flow hedges in accumulated other comprehensive loss for the year ended December 31, 2016 is as follows:
| Effective Portion | ||||||||||||||||
| Hedge Loss Recognized in Other Comprehensive Income (Loss) | Income Statement Location of Loss Reclassification from Accumulated Other Comprehensive Loss | Hedge Loss Reclassified from Accumulated Other Comprehensive Loss | Ineffective Portion | |||||||||||||
| Type of Cash Flow Hedge | Income Statement Location of Loss Recognized | Hedge Loss Recognized | ||||||||||||||
| Year ended December 31, 2016 | ||||||||||||||||
| Forward starting pay fixed swaps | $ | (140 | ) | Interest expense | $ | (6 | ) | Net realized (losses) gains on financial instruments | $ | (8 | ) |
-98-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Income Statement Relationship of Fair Value and Cash Flow Hedging
A summary of the relationship between the effects of fair value and cash flow hedges on the total amount of income and expense presented in our consolidated statements of income for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Classification and Amount of Gain (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships | |||||||||||||||||||||||
| 2018 | 2017 | 2016 | |||||||||||||||||||||
| Net Realized (Losses) Gains on Financial Instruments | Interest Expense | Net Realized (Losses) Gains on Financial Instruments | Interest Expense | Net Realized (Losses) Gains on Financial Instruments | Interest Expense | ||||||||||||||||||
| Total amount of income or expense in the income statement in which the effects of fair value or cash flow hedges are recorded | $ | (180 | ) | $ | (753 | ) | $ | 145 | $ | (739 | ) | $ | 5 | $ | (723 | ) | |||||||
| Gain (loss) on fair value hedging relationships: | |||||||||||||||||||||||
| Interest rate swaps: | |||||||||||||||||||||||
| Hedged items | — | — | — | — | — | (8 | ) | ||||||||||||||||
| Derivatives designated as hedging instruments | — | — | — | — | — | 8 | |||||||||||||||||
| Loss on cash flow hedging relationships: | |||||||||||||||||||||||
| Forward starting pay fixed swaps: | |||||||||||||||||||||||
| Amount of loss reclassified from accumulated other comprehensive loss into net income | — | (14 | ) | — | (7 | ) | — | (6 | ) | ||||||||||||||
| Amount of loss reclassified from accumulated other comprehensive loss into net income due to ineffectiveness and missed forecasted transactions | — | — | (7 | ) | — | (8 | ) | — |
-99-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Non-Hedging Derivatives
A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Type of Non-hedging Derivatives | Income Statement Location of Gain (Loss) Recognized | Derivative Gain (Loss) Recognized | ||||
| Year ended December 31, 2018 | ||||||
| Interest rate swaps | Net realized (losses) gains on financial instruments | $ | 14 | |||
| Options | Net realized (losses) gains on financial instruments | 1 | ||||
| Futures | Net realized (losses) gains on financial instruments | 8 | ||||
| Total | $ | 23 | ||||
| Year ended December 31, 2017 | ||||||
| Interest rate swaps | Net realized (losses) gains on financial instruments | $ | (9 | ) | ||
| Options | Net realized (losses) gains on financial instruments | (36 | ) | |||
| Futures | Net realized (losses) gains on financial instruments | (3 | ) | |||
| Total | $ | (48 | ) | |||
| Year ended December 31, 2016 | ||||||
| Interest rate swaps | Net realized (losses) gains on financial instruments | $ | 1 | |||
| Options | Net realized (losses) gains on financial instruments | (209 | ) | |||
| Futures | Net realized (losses) gains on financial instruments | 1 | ||||
| Total | $ | (207 | ) |
- Fair Value
Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
| Level Input: | Input Definition: | |
| Level I | Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. | |
| Level II | Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date. | |
| Level III | Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. |
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less, and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States Government securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls
-100-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Other invested assets, current: Other invested assets, current include securities held in rabbi trusts that are classified as trading. These securities are designated Level I securities as fair values are based on quoted market prices.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar derivative transactions. Derivatives are designated as Level II securities.
In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan assets not defined above (see Note 10, “Retirement Benefits,” for fair values of benefit plan assets):
Mutual funds: Fair values are based on quoted market prices, which represent the net asset value, or NAV, of the shares held.
Common and collective trusts: Fair values of common/collective trusts that replicate traded money market funds are based on cost, which approximates fair value. Fair values of common/collective trusts that invest in securities are valued at the NAV of the shares held, where the trust applies fair value measurements to the underlying investments to determine the NAV.
Partnership interests: Fair values are estimated based on the plan’s proportionate share of the undistributed partners’ capital as reported in audited financial statements of the partnership.
Contract with insurance company: Fair value of the contract in the insurance company general investment account is determined by the insurance company based on the fair value of the underlying investments of the account.
Investment in DOL 103-12 trust: Fair value is based on the plan’s proportionate share of the fair value of investments held by the trust, qualified as a Department of Labor Regulation 2520.103-12 entity, or DOL 103-12 trust, as reported in the audited financial statements of the trust, where the trustee applies fair value measurements to the underlying investments of the trust.
Life insurance contracts: Fair value is based on the cash surrender value of the policies as reported by the insurer.
-101-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December 31, 2018 and 2017 is as follows:
| Level I | Level II | Level III | Total | ||||||||||||
| December 31, 2018 | |||||||||||||||
| Assets: | |||||||||||||||
| Cash equivalents | $ | 1,815 | $ | — | $ | — | $ | 1,815 | |||||||
| Fixed maturity securities, available-for-sale: | |||||||||||||||
| United States Government securities | — | 416 | — | 416 | |||||||||||
| Government sponsored securities | — | 108 | — | 108 | |||||||||||
| States, municipalities and political subdivisions, tax-exempt | — | 4,785 | — | 4,785 | |||||||||||
| Corporate securities | 2 | 7,648 | 287 | 7,937 | |||||||||||
| Residential mortgage-backed securities | — | 2,744 | 6 | 2,750 | |||||||||||
| Commercial mortgage-backed securities | — | 67 | — | 67 | |||||||||||
| Other securities | — | 1,099 | 17 | 1,116 | |||||||||||
| Total fixed maturity securities, available-for-sale | 2 | 16,867 | 310 | 17,179 | |||||||||||
| Equity securities: | |||||||||||||||
| Exchange traded funds | 2 | — | — | 2 | |||||||||||
| Fixed maturity mutual funds | — | 557 | — | 557 | |||||||||||
| Common equity securities | 601 | 53 | — | 654 | |||||||||||
| Private equity securities | — | — | 313 | 313 | |||||||||||
| Total equity securities | 603 | 610 | 313 | 1,526 | |||||||||||
| Other invested assets, current | 21 | — | — | 21 | |||||||||||
| Securities lending collateral | 314 | 290 | — | 604 | |||||||||||
| Derivatives | — | 16 | — | 16 | |||||||||||
| Total assets | $ | 2,755 | $ | 17,783 | $ | 623 | $ | 21,161 | |||||||
| Liabilities: | |||||||||||||||
| Derivatives | $ | — | $ | (17 | ) | $ | — | $ | (17 | ) | |||||
| Total liabilities | $ | — | $ | (17 | ) | $ | — | $ | (17 | ) | |||||
| December 31, 2017 | |||||||||||||||
| Assets: | |||||||||||||||
| Cash equivalents | $ | 1,956 | $ | — | $ | — | $ | 1,956 | |||||||
| Fixed maturity securities, available-for-sale: | |||||||||||||||
| United States Government securities | — | 645 | — | 645 | |||||||||||
| Government sponsored securities | — | 90 | — | 90 | |||||||||||
| States, municipalities and political subdivisions, tax-exempt | — | 6,035 | — | 6,035 | |||||||||||
| Corporate securities | 25 | 7,232 | 229 | 7,486 | |||||||||||
| Residential mortgage-backed securities | — | 2,534 | 5 | 2,539 | |||||||||||
| Commercial mortgage-backed securities | — | 79 | — | 79 | |||||||||||
| Other securities | 75 | 973 | 16 | 1,064 | |||||||||||
| Total fixed maturity securities, available-for-sale | 100 | 17,588 | 250 | 17,938 | |||||||||||
| Equity securities: | |||||||||||||||
| Exchange traded funds | 1,300 | — | — | 1,300 | |||||||||||
| Fixed maturity mutual funds | — | 791 | — | 791 | |||||||||||
| Common equity securities | 1,147 | 107 | — | 1,254 | |||||||||||
| Private equity securities | — | — | 287 | 287 | |||||||||||
| Total equity securities | 2,447 | 898 | 287 | 3,632 | |||||||||||
| Other invested assets, current | 17 | — | — | 17 | |||||||||||
| Securities lending collateral | 214 | 241 | — | 455 | |||||||||||
| Derivatives | — | 3 | — | 3 | |||||||||||
| Total assets | $ | 4,734 | $ | 18,730 | $ | 537 | $ | 24,001 | |||||||
| Liabilities: | |||||||||||||||
| Derivatives | $ | — | $ | (21 | ) | $ | — | $ | (21 | ) | |||||
| Total liabilities | $ | — | $ | (21 | ) | $ | — | $ | (21 | ) |
-102-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Corporate Securities | Residential Mortgage- backed Securities | Commercial Mortgage- backed Securities | Other Securities | Equity Securities | Total | ||||||||||||||||||
| Year ended December 31, 2018 | |||||||||||||||||||||||
| Beginning balance at January 1, 2018 | $ | 229 | $ | 5 | $ | — | $ | 16 | $ | 287 | $ | 537 | |||||||||||
| Total gains (losses): | |||||||||||||||||||||||
| Recognized in net income | 1 | — | — | — | (229 | ) | (228 | ) | |||||||||||||||
| Recognized in accumulated other comprehensive loss | (5 | ) | — | — | — | — | (5 | ) | |||||||||||||||
| Purchases | 120 | 2 | — | 18 | 290 | 430 | |||||||||||||||||
| Sales | (33 | ) | — | — | (1 | ) | (35 | ) | (69 | ) | |||||||||||||
| Settlements | (88 | ) | (1 | ) | — | (10 | ) | — | (99 | ) | |||||||||||||
| Transfers into Level III | 65 | — | — | 9 | — | 74 | |||||||||||||||||
| Transfers out of Level III | (2 | ) | — | — | (15 | ) | — | (17 | ) | ||||||||||||||
| Ending balance at December 31, 2018 | $ | 287 | $ | 6 | $ | — | $ | 17 | $ | 313 | $ | 623 | |||||||||||
| Change in unrealized losses included in net income related to assets still held at December 31, 2018 | $ | — | $ | — | $ | — | $ | — | $ | 30 | $ | 30 | |||||||||||
| Year ended December 31, 2017 | |||||||||||||||||||||||
| Beginning balance at January 1, 2017 | $ | 239 | $ | 11 | $ | — | $ | 43 | $ | 188 | $ | 481 | |||||||||||
| Total (losses) gains: | |||||||||||||||||||||||
| Recognized in net income | (1 | ) | — | — | — | — | (1 | ) | |||||||||||||||
| Recognized in accumulated other comprehensive loss | 3 | — | — | — | 11 | 14 | |||||||||||||||||
| Purchases | 88 | 4 | — | 36 | 89 | 217 | |||||||||||||||||
| Sales | (48 | ) | (5 | ) | — | (1 | ) | (1 | ) | (55 | ) | ||||||||||||
| Settlements | (64 | ) | (2 | ) | — | (7 | ) | — | (73 | ) | |||||||||||||
| Transfers into Level III | 15 | 3 | — | 15 | — | 33 | |||||||||||||||||
| Transfers out of Level III | (3 | ) | (6 | ) | — | (70 | ) | — | (79 | ) | |||||||||||||
| Ending balance at December 31, 2017 | $ | 229 | $ | 5 | $ | — | $ | 16 | $ | 287 | $ | 537 | |||||||||||
| Change in unrealized losses included in net income related to assets still held at December 31, 2017 | $ | (3 | ) | $ | — | $ | — | $ | — | $ | — | $ | (3 | ) | |||||||||
| Year ended December 31, 2016 | |||||||||||||||||||||||
| Beginning balance at January 1, 2016 | $ | 186 | $ | — | $ | 2 | $ | 26 | $ | 102 | $ | 316 | |||||||||||
| Total (losses) gains: | |||||||||||||||||||||||
| Recognized in net income | (3 | ) | — | — | — | 1 | (2 | ) | |||||||||||||||
| Recognized in accumulated other comprehensive loss | (2 | ) | — | — | (1 | ) | (1 | ) | (4 | ) | |||||||||||||
| Purchases | 170 | 4 | — | — | 223 | 397 | |||||||||||||||||
| Sales | (5 | ) | — | — | — | (137 | ) | (142 | ) | ||||||||||||||
| Settlements | (57 | ) | — | — | (1 | ) | — | (58 | ) | ||||||||||||||
| Transfers into Level III | 7 | 9 | — | 29 | — | 45 | |||||||||||||||||
| Transfers out of Level III | (57 | ) | (2 | ) | (2 | ) | (10 | ) | — | (71 | ) | ||||||||||||
| Ending balance at December 31, 2016 | $ | 239 | $ | 11 | $ | — | $ | 43 | $ | 188 | $ | 481 | |||||||||||
| Change in unrealized losses included in net income related to assets still held at December 31, 2016 | $ | (2 | ) | $ | — | $ | — | $ | — | $ | — | $ | (2 | ) |
There were no individually material transfers into or out of Level III during the years ended December 31, 2018, 2017 or 2016.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes or other valuation techniques. These techniques are significantly affected by our assumptions,
-103-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
including discount rates and estimates of future cash flows. Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the years ended December 31, 2018, 2017 or 2016.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of America’s 1st Choice on February 15, 2018. The net assets acquired in our acquisition of America’s 1st Choice and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of America’s 1st Choice assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisition of America’s 1st Choice were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisition of America’s 1st Choice described above, there were no other material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2018 or 2017.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, accrued investment income, premium receivables, self-funded receivables, other receivables, income taxes receivable, unearned income, accounts payable and accrued expenses, security trades pending payable, securities lending payable and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value on the consolidated balance sheets:
Other invested assets, long-term: Other invested assets, long-term primarily include our investments in limited partnerships, joint ventures and other non-controlled corporations, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt - commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.
Long-term debt - senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.
-104-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at December 31, 2018 and 2017 are as follows:
| Carrying Value | Estimated Fair Value | ||||||||||||||||||
| Level I | Level II | Level III | Total | ||||||||||||||||
| December 31, 2018 | |||||||||||||||||||
| Assets: | |||||||||||||||||||
| Other invested assets, long-term | $ | 3,726 | $ | — | $ | — | $ | 3,726 | $ | 3,726 | |||||||||
| Liabilities: | |||||||||||||||||||
| Debt: | |||||||||||||||||||
| Short-term borrowings | 1,145 | — | 1,145 | — | 1,145 | ||||||||||||||
| Commercial paper | 697 | — | 697 | — | 697 | ||||||||||||||
| Notes | 17,178 | — | 17,145 | — | 17,145 | ||||||||||||||
| Convertible debentures | 191 | — | 1,030 | — | 1,030 | ||||||||||||||
| December 31, 2017 | |||||||||||||||||||
| Assets: | |||||||||||||||||||
| Other invested assets, long-term | $ | 3,344 | $ | — | $ | — | $ | 3,344 | $ | 3,344 | |||||||||
| Liabilities: | |||||||||||||||||||
| Debt: | |||||||||||||||||||
| Short-term borrowings | 1,275 | — | 1,275 | — | 1,275 | ||||||||||||||
| Commercial paper | 804 | — | 804 | — | 804 | ||||||||||||||
| Notes | 17,593 | — | 18,815 | — | 18,815 | ||||||||||||||
| Convertible debentures | 260 | — | 1,216 | — | 1,216 |
-105-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
- Income Taxes
The components of deferred income taxes at December 31, 2018 and 2017 are as follows:
| 2018 | 2017 | ||||||
| Deferred tax assets relating to: | |||||||
| Retirement benefits | $ | 226 | $ | 211 | |||
| Accrued expenses | 301 | 279 | |||||
| Insurance reserves | 96 | 136 | |||||
| Net operating loss carryforwards | 7 | 4 | |||||
| Bad debt reserves | 104 | 128 | |||||
| State income tax | 32 | 33 | |||||
| Deferred compensation | 20 | 24 | |||||
| Investment basis difference | — | 24 | |||||
| Unrealized losses on securities | 41 | — | |||||
| Other | 72 | 81 | |||||
| Total deferred tax assets | 899 | 920 | |||||
| Deferred tax liabilities relating to: | |||||||
| Investment basis difference | 52 | — | |||||
| Unrealized gains on securities | — | 175 | |||||
| Intangible assets: | |||||||
| Trademarks and state Medicaid licenses | 1,529 | 1,529 | |||||
| Customer, provider and hospital relationships | 290 | 186 | |||||
| Internally developed software and other amortization differences | 461 | 324 | |||||
| Retirement benefits | 183 | 170 | |||||
| Debt discount | 27 | 28 | |||||
| State deferred tax | 105 | 105 | |||||
| Depreciation and amortization | 47 | 41 | |||||
| Other | 165 | 89 | |||||
| Total deferred tax liabilities | 2,859 | 2,647 | |||||
| Net deferred tax liability | $ | 1,960 | $ | 1,727 |
Significant components of the provision for income taxes for the years ended December 31, 2018, 2017 and 2016 consist of the following:
| 2018 | 2017 | 2016 | |||||||||
| Current tax expense: | |||||||||||
| Federal | $ | 1,128 | $ | 1,356 | $ | 1,862 | |||||
| State and local | 78 | 39 | 94 | ||||||||
| Total current tax expense | 1,206 | 1,395 | 1,956 | ||||||||
| Deferred tax expense (benefit) | 112 | (1,274 | ) | 129 | |||||||
| Total income tax expense | $ | 1,318 | $ | 121 | $ | 2,085 |
State and local current tax expense is reported gross of federal benefit, and includes amounts related to audit settlements, uncertain tax positions, state tax credits and true up of prior years’ tax. Such items are included in multiple lines in the following rate reconciliation table on a net of federal tax basis.
-106-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December 31, 2018, 2017 and 2016 is as follows:
| 2018 | 2017 | 2016 | ||||||||||||||||||
| Amount | Percent | Amount | Percent | Amount | Percent | |||||||||||||||
| Amount at statutory rate | $ | 1,064 | 21.0 | % | $ | 1,387 | 35.0 | % | $ | 1,594 | 35.0 | % | ||||||||
| State and local income taxes net of federal tax expense/benefit | 63 | 1.2 | (2 | ) | (0.1 | ) | 62 | 1.4 | ||||||||||||
| Tax exempt interest and dividends received deduction | (27 | ) | (0.5 | ) | (58 | ) | (1.4 | ) | (62 | ) | (1.4 | ) | ||||||||
| HIP Fee | 324 | 6.4 | — | — | 412 | 9.0 | ||||||||||||||
| Tax Cuts and Jobs Act | (28 | ) | (0.6 | ) | (1,108 | ) | (27.9 | ) | — | — | ||||||||||
| Other, net | (78 | ) | (1.5 | ) | (98 | ) | (2.5 | ) | 79 | 1.8 | ||||||||||
| Total income tax expense | $ | 1,318 | 26.0 | % | $ | 121 | 3.1 | % | $ | 2,085 | 45.8 | % |
During the year ended December 31, 2018, we recognized income tax expense of $324, or $1.23 per diluted share, as a result of the non-tax deductibility of the HIP Fee payment. On December 22, 2017, the federal government enacted the Tax Cuts and Jobs Act, which contains significant changes to corporate taxation, including, but not limited to, reducing the U.S. federal corporate income tax rate from 35% to 21% and modifying or limiting many business deductions. At December 31, 2018, we have completed our accounting for the tax effects of enactment of the Tax Cuts and Jobs Act. There was no material change to our 2017 provisional amount. In addition we reclassified, for our interim and annual reporting periods beginning on January 1, 2018, $91 of stranded tax effects from accumulated other comprehensive loss to retained earnings on our consolidated balance sheet.
During the year ended December 31, 2017, we recognized an income tax benefit of $1,108, or $4.14 per diluted share, as a result of the provisional amount recorded related to the remeasurement of our deferred tax balance as a result of the enactment of the Tax Cuts and Jobs Act. The HIP Fee payment was suspended for 2017.
During the year ended December 31, 2016, we recognized income tax expense of $412, or $1.54 per diluted share, as a result of the non-tax deductibility of the HIP Fee payments.
The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December 31, 2018 and 2017 is as follows:
| 2018 | 2017 | ||||||
| Balance at January 1 | $ | 190 | $ | 131 | |||
| Additions based on: | |||||||
| Tax positions related to current year | 35 | 3 | |||||
| Tax positions related to prior years | 50 | 83 | |||||
| Reductions based on: | |||||||
| Tax positions related to prior years | (31 | ) | (18 | ) | |||
| Settlements with taxing authorities | (3 | ) | (9 | ) | |||
| Balance at December 31 | $ | 241 | $ | 190 |
The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is included in the amounts described in the following paragraph.
The amount of unrecognized tax benefits that would impact our effective tax rate in future periods, if recognized, was $237 and $175 at December 31, 2018 and 2017, respectively. Also included in the table above, at December 31, 2018, is $2 that would be recognized as an adjustment to additional paid-in capital, which would not affect our effective tax rate. In
-107-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
addition to the contingent liabilities included in the table above, during 2017 we filed protective state income tax refund claims of approximately $310. There were no equivalent protective state income tax refund claims filed in 2018.
For the years ended December 31, 2018, 2017 and 2016, we recognized net interest expense of $15, $3 and $7, respectively. We had accrued approximately $37 and $22 for the payment of interest at December 31, 2018 and 2017, respectively.
As of December 31, 2018, as further described below, certain tax years remain open to examination by the Internal Revenue Service, or IRS, and various state and local authorities. In addition, we continue to discuss certain industry issues with the IRS. As a result of these examinations and discussions, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items. However, the ultimate resolution of these items is dependent on the completion of negotiations with various taxing authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible that one could occur in the next twelve months and our unrecognized tax benefits could change within a range of approximately $(54) to $(158).
We are a member of the IRS Compliance Assurance Process, or CAP. The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.
As of December 31, 2018, the IRS examination of our 2018 and 2017 tax years continues to be in process.
In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported with selling, general and administrative expense.
At December 31, 2018, we had unused federal tax net operating loss carryforwards of approximately $20 to offset future taxable income. The loss carryforwards expire in the years 2032 through 2037. During 2018, 2017 and 2016, federal income taxes paid totaled $738, $1,503 and $1,665, respectively.
- Property and Equipment
A summary of property and equipment at December 31, 2018 and 2017 is as follows:
| 2018 | 2017 | ||||||
| Computer software, purchased and internally developed | $ | 3,532 | $ | 2,613 | |||
| Computer equipment, furniture and other equipment | 1,266 | 1,080 | |||||
| Leasehold improvements | 563 | 494 | |||||
| Building and improvements | 169 | 168 | |||||
| Land and improvements | 18 | 18 | |||||
| Property and equipment, gross | 5,548 | 4,373 | |||||
| Accumulated depreciation and amortization | (2,813 | ) | (2,198 | ) | |||
| Property and equipment, net | $ | 2,735 | $ | 2,175 |
Depreciation expense for 2018, 2017 and 2016 was $124, $111 and $104, respectively. Amortization expense on computer software and leasehold improvements for 2018, 2017 and 2016 was $528, $490 and $472, respectively, which includes amortization expense on computer software, both purchased and internally developed, for 2018, 2017 and 2016 of $465, $435 and $412, respectively. Capitalized costs related to the internal development of software of $3,226 and $2,373 at December 31, 2018 and 2017, respectively, are reported with computer software.
During the years ended December 31, 2018, 2017 and 2016, we recognized $5, $2 and $25, respectively, of impairments related to computer software, primarily internally developed. We also recognized $20 of impairments related to computer equipment in 2016. These impairments were due to project cancellation or asset replacement, some of which resulted from a change in strategic focus needed to effectively manage business operations in a post-ACA environment.
-108-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
- Goodwill and Other Intangible Assets
A summary of the change in the carrying amount of goodwill for our segments (see Note 19, “Segment Information”) for 2018 and 2017 is as follows:
| Commercial and Specialty Business | Government Business | Other | Total | ||||||||||||
| Balance as of January 1, 2017 | $ | 11,818 | $ | 5,743 | $ | — | $ | 17,561 | |||||||
| Acquisitions | — | 1,659 | 11 | 1,670 | |||||||||||
| Balance as of December 31, 2017 | 11,818 | 7,402 | 11 | 19,231 | |||||||||||
| Acquisitions | — | 1,285 | — | 1,285 | |||||||||||
| Adjustments | (267 | ) | 266 | (11 | ) | (12 | ) | ||||||||
| Balance as of December 31, 2018 | $ | 11,551 | $ | 8,953 | $ | — | $ | 20,504 | |||||||
| Accumulated impairment as of December 31, 2018 | $ | (41 | ) | $ | — | $ | — | $ | (41 | ) |
The increase in goodwill in 2018 was primarily due to the acquisition of America's 1st Choice in February 2018. The increase in goodwill in 2017 was primarily due to the acquisition of HealthSun in December 2017. For additional information regarding these acquisitions, see Note 3, “Business Acquisitions”.
The adjustments in 2018 include measurement period adjustments for HealthSun as well as certain reclassifications made for segment reporting. For additional information, see Note 19, “Segment Information”.
As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2018, 2017 and 2016. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and require a significant degree of management judgment and the use of subjective assumptions. Qualitative testing procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity specific events. For quantitative testing, the fair values are estimated using the projected income and market valuation approaches, incorporating Level III internal estimates for inputs, including, but not limited to, revenue projections, income projections, cash flows and discount rates. We did not incur any impairment losses in 2018, 2017 or 2016, as the estimated fair values of our reporting units were substantially in excess of their carrying values.
The components of other intangible assets as of December 31, 2018 and 2017 are as follows:
| 2018 | 2017 | ||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | ||||||||||||||||||
| Intangible assets with finite lives: | |||||||||||||||||||||||
| Customer relationships | $ | 4,495 | $ | (3,185 | ) | $ | 1,310 | $ | 3,725 | $ | (2,878 | ) | $ | 847 | |||||||||
| Provider and hospital relationships | 228 | (85 | ) | 143 | 187 | (73 | ) | 114 | |||||||||||||||
| Other | 352 | (88 | ) | 264 | 184 | (67 | ) | 117 | |||||||||||||||
| Total | 5,075 | (3,358 | ) | 1,717 | 4,096 | (3,018 | ) | 1,078 | |||||||||||||||
| Intangible assets with indefinite lives: | |||||||||||||||||||||||
| Blue Cross and Blue Shield and other trademarks | 6,299 | — | 6,299 | 6,299 | — | 6,299 | |||||||||||||||||
| State Medicaid licenses | 991 | — | 991 | 991 | — | 991 | |||||||||||||||||
| Total | 7,290 | — | 7,290 | 7,290 | — | 7,290 | |||||||||||||||||
| Other intangible assets | $ | 12,365 | $ | (3,358 | ) | $ | 9,007 | $ | 11,386 | $ | (3,018 | ) | $ | 8,368 |
-109-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
As of December 31, 2018, the estimated amortization expense for each of the five succeeding years is as follows: 2019, $337; 2020, $289; 2021, $243; 2022, $195; and 2023, $161.
- Retirement Benefits
We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.
The Anthem Cash Balance Plan A and the Anthem Cash Balance Plan B are cash balance pension plans covering certain eligible employees of the affiliated companies that participate in these plans. Effective January 1, 2006, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants who met grandfathering rules continued to accrue benefits. Participants who did not receive credits and/or benefit accruals are included in the Anthem Cash Balance Plan A, while employees who were still receiving credits and/or benefits participate in the Anthem Cash Balance Plan B. Effective January 1, 2019, benefits under the Anthem Cash Balance Plan B were curtailed. All grandfathered participants will no longer have pay credits added to their accounts but will continue to earn interest on existing account balances. Participants will continue to earn years of pension service for vesting purposes. Several pension plans acquired through various corporate mergers and acquisitions have been merged into these plans in prior years.
The UGS Pension Plan is a defined benefit pension plan with a cash balance component. The UGS Pension Plan covers eligible employees of the affiliated companies that participate in the UGS Pension Plan. Effective January 1, 2004, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits previously accrued. Certain employees subject to collective bargaining agreements and certain other employees who met grandfathering rules continue to accrue benefits. Effective December 31, 2017, the UGS Pension Plan was merged into the Anthem Cash Balance Plan B.
The Employees’ Retirement Plan of Blue Cross of California, or the BCC Plan, is a defined benefit pension plan that covers eligible employees of Blue Cross of California who are covered by a collective bargaining agreement. Effective January 1, 2007, benefits were curtailed under the BCC Plan with the result that no Blue Cross of California employees hired or rehired after December 31, 2006 are eligible to participate in the BCC Plan.
All of the plans’ assets consist primarily of common stocks, fixed maturity securities, investment funds and short-term investments. The funding policies for all plans are to contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended, or ERISA, including amendments by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are necessary to provide assets sufficient to meet the benefits to be paid to plan participants.
We use a December 31 measurement date for determining benefit obligations and fair value of plan assets.
The following tables disclose consolidated “pension benefits,” which include the defined benefit pension plans described above, and consolidated “other benefits,” which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were computed using assumptions at the December 31 measurement dates.
The reconciliation of the benefit obligation is as follows:
| Pension Benefits | Other Benefits | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| Benefit obligation at beginning of year | $ | 1,872 | $ | 1,825 | $ | 524 | $ | 565 | |||||||
| Service cost | 8 | 10 | 1 | 1 | |||||||||||
| Interest cost | 55 | 66 | 15 | 21 | |||||||||||
| Actuarial (gain) loss | (70 | ) | 104 | (57 | ) | (39 | ) | ||||||||
| Benefits paid | (122 | ) | (133 | ) | (52 | ) | (24 | ) | |||||||
| Benefit obligation at end of year | $ | 1,743 | $ | 1,872 | $ | 431 | $ | 524 |
-110-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The changes in the fair value of plan assets are as follows:
| Pension Benefits | Other Benefits | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| Fair value of plan assets at beginning of year | $ | 2,012 | $ | 1,888 | $ | 356 | $ | 332 | |||||||
| Actual return on plan assets | (76 | ) | 253 | (17 | ) | 41 | |||||||||
| Employer contributions | 4 | 4 | 49 | 7 | |||||||||||
| Benefits paid | (122 | ) | (133 | ) | (52 | ) | (24 | ) | |||||||
| Fair value of plan assets at end of year | $ | 1,818 | $ | 2,012 | $ | 336 | $ | 356 |
The net amount included in the consolidated balance sheets is as follows:
| Pension Benefits | Other Benefits | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| Noncurrent assets | $ | 134 | $ | 202 | $ | — | $ | — | |||||||
| Current liabilities | (6 | ) | (5 | ) | — | — | |||||||||
| Noncurrent liabilities | (53 | ) | (57 | ) | (95 | ) | (168 | ) | |||||||
| Net amount at December 31 | $ | 75 | $ | 140 | $ | (95 | ) | $ | (168 | ) |
The net amounts included in accumulated other comprehensive loss that have not been recognized as components of net periodic benefit costs are as follows:
| Pension Benefits | Other Benefits | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| Net actuarial loss | $ | 751 | $ | 625 | $ | 58 | $ | 77 | |||||||
| Prior service cost (credit) | 1 | 1 | (34 | ) | (46 | ) | |||||||||
| Net amount before tax at December 31 | $ | 752 | $ | 626 | $ | 24 | $ | 31 |
The estimated net actuarial loss and prior service cost for the defined benefit pension plans that will be reclassified from accumulated other comprehensive loss into net periodic benefit costs over the next year are $16 and $0, respectively. The estimated net actuarial loss and prior service credit for postretirement benefit plans that will be reclassified from accumulated other comprehensive loss into net periodic benefit costs over the next year are $2 and $12, respectively.
The accumulated benefit obligation for the defined benefit pension plans was $1,742 and $1,869 at December 31, 2018 and 2017, respectively.
As of December 31, 2018, certain pension plans had accumulated benefit obligations in excess of plan assets. For those same plans, the projected benefit obligation was also in excess of plan assets. Such plans had a combined projected benefit obligation, accumulated benefit obligation and fair value of plan assets of $94, $93 and $36, respectively.
The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:
| Pension Benefits | Other Benefits | ||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||
| Discount rate | 4.15 | % | 3.44 | % | 4.04 | % | 3.42 | % | |||
| Rate of compensation increase | 3.00 | % | 3.00 | % | 3.00 | % | 3.00 | % | |||
| Expected rate of return on plan assets | 7.44 | % | 7.83 | % | 7.00 | % | 7.00 | % |
-111-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The components of net periodic benefit credit included in the consolidated statements of income are as follows:
| 2018 | 2017 | 2016 | |||||||||
| Pension Benefits | |||||||||||
| Service cost | $ | 8 | $ | 10 | $ | 12 | |||||
| Interest cost | 55 | 66 | 69 | ||||||||
| Expected return on assets | (147 | ) | (147 | ) | (147 | ) | |||||
| Recognized actuarial loss | 22 | 22 | 19 | ||||||||
| Amortization of prior service credit | — | — | (1 | ) | |||||||
| Settlement loss | 5 | 7 | 7 | ||||||||
| Net periodic benefit credit | $ | (57 | ) | $ | (42 | ) | $ | (41 | ) | ||
| Other Benefits | |||||||||||
| Service cost | $ | 1 | $ | 1 | $ | 2 | |||||
| Interest cost | 15 | 21 | 22 | ||||||||
| Expected return on assets | (24 | ) | (23 | ) | (22 | ) | |||||
| Recognized actuarial loss | 3 | 11 | 12 | ||||||||
| Amortization of prior service credit | (12 | ) | (13 | ) | (14 | ) | |||||
| Net periodic benefit credit | $ | (17 | ) | $ | (3 | ) | $ | — |
During the years ended December 31, 2018, 2017 and 2016 we incurred total settlement losses of $5, $7 and $7, respectively, as lump-sum payments exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.
The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:
| 2018 | 2017 | 2016 | ||||||
| Pension Benefits | ||||||||
| Discount rate | 3.44 | % | 3.77 | % | 3.92 | % | ||
| Rate of compensation increase | 3.00 | % | 3.00 | % | 3.00 | % | ||
| Expected rate of return on plan assets | 7.83 | % | 7.95 | % | 7.84 | % | ||
| Other Benefits | ||||||||
| Discount rate | 3.42 | % | 3.82 | % | 4.01 | % | ||
| Rate of compensation increase | 3.00 | % | 3.00 | % | 3.00 | % | ||
| Expected rate of return on plan assets | 7.00 | % | 7.00 | % | 7.00 | % |
The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December 31, 2018 measurement date was 7.50% for 2019 with a gradual decline to 4.50% by the year 2028. The assumed healthcare cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2018 measurement date was 6.00% for 2019 with a gradual decline to 4.50% by the year 2028. These estimated trend rates are subject to change in the future. The healthcare cost trend rate assumption affects the amounts reported. For example, an increase in the assumed healthcare cost trend rate of one percentage point would increase the postretirement benefit obligation as of December 31, 2018 by $24 and would increase service and interest costs by $1. Conversely, a decrease in the assumed healthcare cost trend rate of one percentage point would decrease the postretirement benefit obligation as of December 31, 2018 by $21 and would decrease service and interest costs by $1.
-112-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Plan assets include a diversified mix of investment grade fixed maturity securities, equity securities and alternative investments across a range of sectors and levels of capitalization to maximize the long-term return for a prudent level of risk. The weighted-average target allocation for pension benefit plan assets is 44% equity securities, 47% fixed maturity securities, and 9% to all other types of investments. Equity securities primarily include a mix of domestic securities, foreign securities and mutual funds invested in equities. Fixed maturity securities primarily include treasury securities, corporate bonds and asset-backed investments issued by corporations and the U.S. government. Other types of investments primarily include partnership interests, collective trusts that replicate money market funds and insurance contracts designed specifically for employee benefit plans. As of December 31, 2018, there were no significant concentrations of investments in the pension benefit assets or other benefit assets. No plan assets were invested in Anthem common stock.
Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value.
The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31, 2018, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $69, are as follows (see Note 6, “Fair Value,” for additional information regarding the definition of level inputs):
| Level I | Level II | Level III | Total | ||||||||||||
| December 31, 2018 | |||||||||||||||
| Pension Benefit Assets: | |||||||||||||||
| Equity securities: | |||||||||||||||
| U.S. securities | $ | 488 | $ | — | $ | — | $ | 488 | |||||||
| Foreign securities | 147 | — | — | 147 | |||||||||||
| Mutual funds | 36 | — | — | 36 | |||||||||||
| Fixed maturity securities: | |||||||||||||||
| Government securities | — | 248 | — | 248 | |||||||||||
| Corporate securities | — | 347 | — | 347 | |||||||||||
| Asset-backed securities | — | 153 | — | 153 | |||||||||||
| Other types of investments: | |||||||||||||||
| Partnership interests | — | — | 187 | 187 | |||||||||||
| Insurance company contracts | — | — | 166 | 166 | |||||||||||
| Total pension benefit assets | $ | 671 | $ | 748 | $ | 353 | $ | 1,772 | |||||||
| Other Benefit Assets: | |||||||||||||||
| Equity securities: | |||||||||||||||
| U.S. securities | $ | 9 | $ | — | $ | — | $ | 9 | |||||||
| Foreign securities | 3 | — | — | 3 | |||||||||||
| Mutual funds | 27 | — | — | 27 | |||||||||||
| Fixed maturity securities: | |||||||||||||||
| Government securities | — | 3 | — | 3 | |||||||||||
| Corporate securities | — | 5 | — | 5 | |||||||||||
| Asset-backed securities | — | 5 | — | 5 | |||||||||||
| Other types of investments: | |||||||||||||||
| Partnership interests | — | — | 2 | 2 | |||||||||||
| Life insurance contracts | — | — | 249 | 249 | |||||||||||
| Investment in DOL 103-12 trust | — | 10 | — | 10 | |||||||||||
| Total other benefit assets | $ | 39 | $ | 23 | $ | 251 | $ | 313 |
-113-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31, 2017, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $14, are as follows:
| Level I | Level II | Level III | Total | ||||||||||||
| December 31, 2017 | |||||||||||||||
| Pension Benefit Assets: | |||||||||||||||
| Equity securities: | |||||||||||||||
| U.S. securities | $ | 584 | $ | 5 | $ | — | $ | 589 | |||||||
| Foreign securities | 179 | — | — | 179 | |||||||||||
| Mutual funds | 39 | — | — | 39 | |||||||||||
| Fixed maturity securities: | |||||||||||||||
| Government securities | 227 | — | — | 227 | |||||||||||
| Corporate securities | — | 377 | — | 377 | |||||||||||
| Asset-backed securities | — | 140 | — | 140 | |||||||||||
| Other types of investments: | |||||||||||||||
| Common and collective trusts | — | 54 | — | 54 | |||||||||||
| Partnership interests | — | — | 221 | 221 | |||||||||||
| Insurance company contracts | — | — | 173 | 173 | |||||||||||
| Total pension benefit assets | $ | 1,029 | $ | 576 | $ | 394 | $ | 1,999 | |||||||
| Other Benefit Assets: | |||||||||||||||
| Equity securities: | |||||||||||||||
| U.S. securities | $ | 10 | $ | — | $ | — | $ | 10 | |||||||
| Foreign securities | 3 | — | — | 3 | |||||||||||
| Mutual funds | 48 | — | — | 48 | |||||||||||
| Fixed maturity securities: | |||||||||||||||
| Government securities | 3 | — | — | 3 | |||||||||||
| Corporate securities | — | 5 | — | 5 | |||||||||||
| Asset-backed securities | — | 5 | — | 5 | |||||||||||
| Other types of investments: | |||||||||||||||
| Common and collective trusts | — | 1 | — | 1 | |||||||||||
| Life insurance contracts | — | — | 269 | 269 | |||||||||||
| Investment in DOL 103-12 trust | — | 11 | — | 11 | |||||||||||
| Total other benefit assets | $ | 64 | $ | 22 | $ | 269 | $ | 355 |
-114-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Partnership Interests | Insurance Company Contracts | Life Insurance Contracts | Total | ||||||||||||
| Year ended December 31, 2018 | |||||||||||||||
| Beginning balance at January 1, 2018 | $ | 221 | $ | 173 | $ | 269 | $ | 663 | |||||||
| Actual return on plan assets relating to assets still held at the reporting date | (10 | ) | (7 | ) | (15 | ) | (32 | ) | |||||||
| Purchases | — | 8 | — | 8 | |||||||||||
| Sales | (22 | ) | (8 | ) | (5 | ) | (35 | ) | |||||||
| Ending balance at December 31, 2018 | $ | 189 | $ | 166 | $ | 249 | $ | 604 | |||||||
| Year ended December 31, 2017 | |||||||||||||||
| Beginning balance at January 1, 2017 | $ | 114 | $ | 173 | $ | 238 | $ | 525 | |||||||
| Actual return on plan assets relating to assets still held at the reporting date | 20 | (1 | ) | 31 | 50 | ||||||||||
| Purchases | 126 | 10 | — | 136 | |||||||||||
| Sales | (39 | ) | (9 | ) | — | (48 | ) | ||||||||
| Ending balance at December 31, 2017 | $ | 221 | $ | 173 | $ | 269 | $ | 663 | |||||||
| Year ended December 31, 2016 | |||||||||||||||
| Beginning balance at January 1, 2016 | $ | 119 | $ | 174 | $ | 230 | $ | 523 | |||||||
| Actual return on plan assets relating to assets still held at the reporting date | (4 | ) | (3 | ) | 11 | 4 | |||||||||
| Purchases | 18 | 9 | — | 27 | |||||||||||
| Sales | (19 | ) | (7 | ) | (3 | ) | (29 | ) | |||||||
| Ending balance at December 31, 2016 | $ | 114 | $ | 173 | $ | 238 | $ | 525 |
During 2018, we transferred our United States Government securities from Level I to Level II based on the inputs used to measure fair value. There were no transfers into or out of Level III during the years ended December 31, 2018, 2017 or 2016.
Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the years ended December 31, 2018, 2017 and 2016, no material contributions were necessary to meet ERISA required funding levels. However, during the years ended December 31, 2018, 2017 and 2016, we made tax deductible discretionary contributions to the pension benefit plans of $4, $4 and $11, respectively. Employer contributions to other benefit plans represent discretionary contributions and do not include payments to retirees for current benefits.
-115-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Our estimated future payments for pension benefits and postretirement benefits, which reflect expected future service, as appropriate, are as follows:
| Pension Benefits | Other Benefits | ||||||
| 2019 | $ | 124 | $ | 37 | |||
| 2020 | 121 | 37 | |||||
| 2021 | 123 | 37 | |||||
| 2022 | 123 | 37 | |||||
| 2023 | 121 | 36 | |||||
| 2024 - 2028 | 575 | 159 |
In addition to the defined benefit plans, we maintain the Anthem 401(k) Plan which is a qualified defined contribution plan covering substantially all employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled $211, $142 and $132 during 2018, 2017 and 2016, respectively. Contributions in 2018 include approximately $58 for a one time contribution made to employees following the enactment of the Tax Cuts and Jobs Act.
- Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 19, “Segment Information”), for the year ended December 31, 2018 is as follows:
| Commercial & Specialty Business | Government Business | Total | |||||||||
| Gross medical claims payable, beginning of year | $ | 3,383 | $ | 4,431 | $ | 7,814 | |||||
| Ceded medical claims payable, beginning of year | (78 | ) | (27 | ) | (105 | ) | |||||
| Net medical claims payable, beginning of year | 3,305 | 4,404 | 7,709 | ||||||||
| Business combinations and purchase adjustments | — | 199 | 199 | ||||||||
| Net incurred medical claims: | |||||||||||
| Current year | 24,094 | 45,487 | 69,581 | ||||||||
| Prior years redundancies | (456 | ) | (474 | ) | (930 | ) | |||||
| Total net incurred medical claims | 23,638 | 45,013 | 68,651 | ||||||||
| Net payments attributable to: | |||||||||||
| Current year medical claims | 21,633 | 41,115 | 62,748 | ||||||||
| Prior years medical claims | 2,734 | 3,845 | 6,579 | ||||||||
| Total net payments | 24,367 | 44,960 | 69,327 | ||||||||
| Net medical claims payable, end of year | 2,576 | 4,656 | 7,232 | ||||||||
| Ceded medical claims payable, end of year | 10 | 24 | 34 | ||||||||
| Gross medical claims payable, end of year | $ | 2,586 | $ | 4,680 | $ | 7,266 |
-116-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2017 is as follows:
| Commercial & Specialty Business | Government Business | Total | |||||||||
| Gross medical claims payable, beginning of year | $ | 3,247 | $ | 4,409 | $ | 7,656 | |||||
| Ceded medical claims payable, beginning of year | (521 | ) | (18 | ) | (539 | ) | |||||
| Net medical claims payable, beginning of year | 2,726 | 4,391 | 7,117 | ||||||||
| Business combinations and purchase adjustments | — | 76 | 76 | ||||||||
| Net incurred medical claims: | |||||||||||
| Current year | 29,467 | 40,910 | 70,377 | ||||||||
| Prior years redundancies | (462 | ) | (671 | ) | (1,133 | ) | |||||
| Total net incurred medical claims | 29,005 | 40,239 | 69,244 | ||||||||
| Net payments attributable to: | |||||||||||
| Current year medical claims | 26,250 | 36,673 | 62,923 | ||||||||
| Prior years medical claims | 2,176 | 3,629 | 5,805 | ||||||||
| Total net payments | 28,426 | 40,302 | 68,728 | ||||||||
| Net medical claims payable, end of year | 3,305 | 4,404 | 7,709 | ||||||||
| Ceded medical claims payable, end of year | 78 | 27 | 105 | ||||||||
| Gross medical claims payable, end of year | $ | 3,383 | $ | 4,431 | $ | 7,814 |
A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2016 is as follows:
| Commercial & Specialty Business | Government Business | Total | |||||||||
| Gross medical claims payable, beginning of year | $ | 3,371 | $ | 3,989 | $ | 7,360 | |||||
| Ceded medical claims payable, beginning of year | (636 | ) | (10 | ) | (646 | ) | |||||
| Net medical claims payable, beginning of year | 2,735 | 3,979 | 6,714 | ||||||||
| Net incurred medical claims: | |||||||||||
| Current year | 27,588 | 37,280 | 64,868 | ||||||||
| Prior years redundancies | (463 | ) | (372 | ) | (835 | ) | |||||
| Total net incurred medical claims | 27,125 | 36,908 | 64,033 | ||||||||
| Net payments attributable to: | |||||||||||
| Current year medical claims | 24,928 | 32,951 | 57,879 | ||||||||
| Prior years medical claims | 2,206 | 3,545 | 5,751 | ||||||||
| Total net payments | 27,134 | 36,496 | 63,630 | ||||||||
| Net medical claims payable, end of year | 2,726 | 4,391 | 7,117 | ||||||||
| Ceded medical claims payable, end of year | 521 | 18 | 539 | ||||||||
| Gross medical claims payable, end of year | $ | 3,247 | $ | 4,409 | $ | 7,656 |
Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period-end are continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the originally established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated. The prior year redundancy of $930 shown above for the year ended December 31, 2018 represents an estimate
-117-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
based on paid claim activity from January 1, 2018 to December 31, 2018. Medical claim liabilities are usually described as having a “short tail,” which means that they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority of the $930 redundancy relates to claims incurred in calendar year 2017.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December 31, 2018, 2017 and 2016, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.
| Favorable Developments by Changes in Key Assumptions | |||||||||||
| 2018 | 2017 | 2016 | |||||||||
| Assumed trend factors | $ | (515 | ) | $ | (631 | ) | $ | (578 | ) | ||
| Assumed completion factors | (415 | ) | (502 | ) | (257 | ) | |||||
| Total | $ | (930 | ) | $ | (1,133 | ) | $ | (835 | ) |
The favorable development recognized in 2018 and 2017 resulted from trend and completion factors developing more favorably than originally expected. The favorable development recognized in 2016 resulted primarily from trend factors in late 2015 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development.
The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:
| Years Ended December 31 | ||||||||||||
| 2018 | 2017 | 2016 | ||||||||||
| Net incurred medical claims: | ||||||||||||
| Commercial & Specialty Business | $ | 23,638 | $ | 29,005 | $ | 27,125 | ||||||
| Government Business | 45,013 | 40,239 | 36,908 | |||||||||
| Total net incurred medical claims | 68,651 | 69,244 | 64,033 | |||||||||
| Quality improvement and other claims expense | 3,244 | 2,992 | 2,801 | |||||||||
| Benefit expense | $ | 71,895 | $ | 72,236 | $ | 66,834 |
Incurred claims development, net of reinsurance, for the Commercial & Specialty Business for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Commercial & Specialty Business | Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance | |||||||||||
| 2016 | 2017 | |||||||||||
| Claim Years | (Unaudited) | (Unaudited) | 2018 | |||||||||
| 2016 & Prior | $ | 29,861 | $ | 29,399 | $ | 29,298 | ||||||
| 2017 | 29,467 | 29,112 | ||||||||||
| 2018 | 24,094 | |||||||||||
| Total | $ | 82,504 |
-118-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Paid claims development, net of reinsurance, for the Commercial & Specialty Business for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Commercial & Specialty Business | Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance | |||||||||||
| 2016 | 2017 | |||||||||||
| Claim Years | (Unaudited) | (Unaudited) | 2018 | |||||||||
| 2016 & Prior | $ | 27,135 | $ | 29,311 | $ | 29,289 | ||||||
| 2017 | 26,250 | 29,006 | ||||||||||
| 2018 | 21,633 | |||||||||||
| Total | $ | 79,928 |
At December 31, 2018, the total of incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was $9, $106 and $2,461 for the claim years 2016 and prior, 2017 and 2018, respectively.
At December 31, 2018, the cumulative number of reported claims for the Commercial & Specialty Business was 120, 117 and 85 for the claim years 2016 and prior, 2017 and 2018, respectively.
Incurred claims development, net of reinsurance, for the Government Business as of and for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Government Business | Cumulative Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance | |||||||||||
| 2016 | 2017 | |||||||||||
| Claim Years | (Unaudited) | (Unaudited) | 2018 | |||||||||
| 2016 & Prior | $ | 40,888 | $ | 40,217 | $ | 40,133 | ||||||
| 2017 | 40,986 | 40,596 | ||||||||||
| 2018 | 45,686 | |||||||||||
| Total | $ | 126,415 |
Paid claims development, net of reinsurance, for the Government Business as of and for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Government Business | Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance | |||||||||||
| 2016 | 2017 | |||||||||||
| Claim Years | (Unaudited) | (Unaudited) | 2018 | |||||||||
| 2016 & Prior | $ | 36,497 | $ | 40,126 | $ | 40,103 | ||||||
| 2017 | 36,673 | 40,541 | ||||||||||
| 2018 | 41,115 | |||||||||||
| Total | $ | 121,759 |
At December 31, 2018, the total of incurred but not reported liabilities plus expected development on reported claims for the Government Business was $30, $55 and $4,571 for the claim years 2016 and prior, 2017 and 2018, respectively.
At December 31, 2018, the cumulative number of reported claims for the Government Business was 209, 211 and 205 for the claim years 2016 and prior, 2017 and 2018, respectively.
The information about incurred claims development, paid claims development and cumulative number of reported claims for the years ended December 31, 2016 and 2017, for both the Commercial & Specialty Business and Government Business, is unaudited and presented as supplementary information.
-119-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The cumulative number of reported claims for each claim year, for both the Commercial & Specialty Business and Government Business, have been developed using historical data captured by our claim payment systems. The provided claim amounts are not a precise tool for understanding utilization of medical services. They could be impacted by a variety of factors including changes in provider billing practices, provider reimbursement arrangements, mix of services, benefit design or processing systems. The cumulative number of reported claims has been provided to comply with FASB accounting standards and is not used by management in its claims analysis. Our cumulative number of reported claims may not be comparable to similar measures reported by other health benefits companies.
The reconciliation of the Commercial & Specialty Business and Government Business incurred and paid claims development information for the three years ended December 31, 2018, reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of December 31, 2018, is as follows:
| Commercial & Specialty Business | Government Business | Total | |||||||||
| Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance | $ | 82,504 | $ | 126,415 | $ | 208,919 | |||||
| Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance | 79,928 | 121,759 | 201,687 | ||||||||
| Net medical claims payable, end of year | 2,576 | 4,656 | 7,232 | ||||||||
| Ceded medical claims payable, end of year | 10 | 24 | 34 | ||||||||
| Insurance lines other than short duration | — | 188 | 188 | ||||||||
| Gross medical claims payable, end of year | $ | 2,586 | $ | 4,868 | $ | 7,454 |
- Debt
Short-term Borrowings
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati and the Federal Home Loan Bank of Atlanta, or collectively, the FHLBs. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At December 31, 2018 and 2017, $645 and $825, respectively, were outstanding under our short-term FHLB borrowings. These outstanding short-term FHLB borrowings at December 31, 2018 and 2017 had fixed interest rates of 2.458% and 1.386%, respectively.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit with separate lenders for general corporate purposes. In 2018, we increased the combined borrowing capacity on these line of credit from $450 to $600. The interest rate on each line of credit is based on the LIBOR rate plus a predetermined rate. Our ability to borrow under the lines of credit is subject to compliance with certain covenants. At December 31, 2018 and 2017, $500 and $450, respectively, were outstanding under our 364-day lines of credit.
-120-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Long-term Debt
The carrying value of long-term debt at December 31, 2018 and 2017 consists of the following:
| 2018 | 2017 | ||||||
| Senior unsecured notes: | |||||||
| 1.875%, due 2018 | $ | — | $ | 625 | |||
| 2.300%, due 2018 | — | 649 | |||||
| 2.250%, due 2019 | 849 | 847 | |||||
| 2.500%, due 2020 | 897 | 895 | |||||
| 4.350%, due 2020 | 688 | 693 | |||||
| 3.700%, due 2021 | 698 | 698 | |||||
| 2.950%, due 2022 | 747 | 746 | |||||
| 3.125%, due 2022 | 846 | 845 | |||||
| 3.300%, due 2023 | 1,000 | 994 | |||||
| 3.350%, due 2024 | 846 | 845 | |||||
| 3.500%, due 2024 | 794 | 793 | |||||
| 3.650%, due 2027 | 1,589 | 1,589 | |||||
| 4.101%, due 2028 | 1,250 | — | |||||
| 5.950%, due 2034 | 334 | 334 | |||||
| 5.850%, due 2036 | 396 | 396 | |||||
| 6.375%, due 2037 | 366 | 366 | |||||
| 5.800%, due 2040 | 124 | 123 | |||||
| 4.625%, due 2042 | 887 | 887 | |||||
| 4.650%, due 2043 | 986 | 986 | |||||
| 4.650%, due 2044 | 791 | 791 | |||||
| 5.100%, due 2044 | 594 | 594 | |||||
| 4.375%, due 2047 | 1,386 | 1,386 | |||||
| 4.550%, due 2048 | 838 | — | |||||
| 4.850%, due 2054 | 247 | 247 | |||||
| Remarketable subordinated notes: | |||||||
| 1.900%, due 2028 | — | 1,239 | |||||
| Surplus note: | |||||||
| 9.000%, due 2027 | 25 | 25 | |||||
| Senior convertible debentures: | |||||||
| 2.750%, due 2042 | 191 | 260 | |||||
| Variable rate debt: | |||||||
| Commercial paper program | 697 | 804 | |||||
| Total long-term debt | 18,066 | 18,657 | |||||
| Current portion of long-term debt | (849 | ) | (1,275 | ) | |||
| Long-term debt, less current portion | $ | 17,217 | $ | 17,382 |
All debt is a direct obligation of Anthem, Inc., except for the surplus note, the FHLB borrowings and the lines of credit.
-121-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
We generally issue senior unsecured notes, or Notes, for long-term borrowing purposes. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating.
On July 16, 2018, we repaid, at maturity, the $650 outstanding balance of our 2.300% senior unsecured notes. On January 15, 2018, we repaid, at maturity, the $625 outstanding balance of our 1.875% senior unsecured notes.
On May 1, 2018, we settled our Equity Units stock purchase contracts at a settlement rate of 0.2412 shares of our common stock, using a market value formula set forth in the Equity Units purchase contracts. This resulted in the issuance of approximately 6 shares. We had issued 25 Equity Units on May 12, 2015, pursuant to an underwriting agreement dated May 6, 2015, in an aggregate principal amount of $1,250. Each Equity Unit had a stated amount of $50 (whole dollars) and consisted of a purchase contract obligating the holder to purchase a certain number of shares of our common stock on May 1, 2018, subject to earlier termination or settlement, for a price in cash of $50 (whole dollars); and a 5% undivided beneficial ownership interest in $1,000 (whole dollars) principal amount of our 1.900% remarketable subordinated notes, or RSNs, due 2028. At December 31, 2017, the stock purchase contract liability was $21 and was included in other current liabilities and other noncurrent liabilities with a corresponding offset to additional paid-in capital in our consolidated balance sheet. Contract adjustment payments commenced on August 1, 2015 at a rate of 3.350% per annum on the stated amount per Equity Unit. The RSNs were pledged as collateral to secure the purchase of common stock under the related stock purchase contracts. Quarterly interest payments on the RSNs commenced on August 1, 2015. On March 2, 2018, we remarketed the RSNs and used the proceeds to purchase U.S. Treasury securities that were pledged to secure the stock purchase obligations of the holders of the Equity Units. The purchasers of the RSNs transferred the RSNs to us in exchange for $1,250 principal amount of our 4.101% senior notes due 2028, or the 2028 Notes, and a cash payment of $4. We cancelled the RSNs upon receipt and recognized a loss on extinguishment of debt of $18. At the remarketing, we also issued $850 aggregate principal amount of 4.550% notes due 2048, or the 2048 Notes, under our shelf registration statement. We used the proceeds from the 2048 Notes for working capital and general corporate purposes. Interest on the 2028 Notes and the 2048 Notes is payable semi-annually in arrears on March 1 and September 1 of each year, commencing on September 1, 2018.
On November 21, 2017, we issued $900 aggregate principal amount of 2.500% Notes due 2020, $750 aggregate principal amount of 2.950% Notes due 2022, $850 aggregate principal amount of 3.350% Notes due 2024, $1,600 aggregate principal amount of 3.650% Notes due 2027 and $1,400 aggregate principal amount of 4.375% Notes due 2047 under our shelf registration statement. Interest on the 2020 Notes is payable semi-annually in arrears on May 21 and November 21 of each year, commencing on May 21, 2018. Interest on the 2022 Notes, the 2024 Notes, the 2027 Notes and the 2047 Notes is payable semi-annually in arrears on June 1 and December 1 of each year, commencing on June 1, 2018. The net proceeds were used to fund the acquisitions of HealthSun and America’s 1st Choice; redemption of the 7.000% Notes due 2019, discussed below; and redemption of the Tender Notes, discussed below.
On November 14, 2017, we initiated a cash tender offer to purchase any and all of our 7.000% Notes due 2019, or the Any and All Notes, and certain of our 5.950% Notes due 2034, 5.850% Notes due 2036, 6.375% Notes due 2037, 5.800% Notes due 2040 and 5.100% Notes due 2044, or the Maximum Tender Offer Notes, and collectively with the Any and All Notes, the Tender Notes. On November 21, 2017, we repurchased $185 aggregate principal amount of the Any and All Notes, plus applicable premium and accrued and unpaid interest, for cash totaling $199. On November 30, 2017, we repurchased $836 aggregate principal amount of the Maximum Tender Offer Notes, plus applicable premium and accrued and unpaid interest, for cash totaling $1,095. We recognized a loss on extinguishment of debt of $266 for the repurchase of the Tender Notes.
On December 14, 2017, we redeemed the $255 remaining outstanding principal balance of our 7.000% Notes due 2019, plus applicable premium for early redemption and accrued and unpaid interest to the redemption date, for cash totaling $275. We recognized a loss on extinguishment of debt of $14 for the repurchase of these Notes.
On June 15, 2017 and February 15, 2017, we repaid, upon maturity, the $529 outstanding balance of our 5.875% Notes and the $400 outstanding balance of our 2.375% Notes, respectively.
The surplus note is an unsecured obligation of Anthem Insurance Companies, Inc., or Anthem Insurance, a wholly owned subsidiary, and is subordinate in right of payment to all of Anthem Insurance’s existing and future indebtedness. Any payment of interest or principal on the surplus note may be made only with the prior approval of the Indiana Department of Insurance,
-122-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
or IDOI, and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available for the payment under Indiana insurance laws.
We have a senior revolving credit facility, or the Facility, with a group of lenders for general corporate purposes. The Facility provides credit up to $3,500 and matures on August 25, 2020. The interest rate on the Facility is based on either the LIBOR rate or a base rate plus a predetermined rate based on our public debt rating at the date of utilization. Our ability to borrow under the Facility is subject to compliance with certain covenants. There were no amounts outstanding under the Facility at December 31, 2018 or 2017.
We have an authorized commercial paper program of up to $2,500, the proceeds of which may be used for general corporate purposes. At December 31, 2018, we had $697 outstanding under our commercial paper program with a weighted-average interest rate of 2.8270%. At December 31, 2017, we had $804 outstanding under our commercial paper program with a weighted-average interest rate of 1.8247%. Commercial paper borrowings have been classified as long-term debt at December 31, 2018 and 2017, as our general practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year, and we have the ability to redeem our commercial paper with borrowings under the Facility described above.
During the year ended December 31, 2015, we entered into a bridge facility commitment letter and a joinder agreement, and a term loan facility, to finance a portion of the consideration under the now terminated Cigna Merger Agreement. In January 2017, we reduced the size of the bridge facility from $22,500 to $19,500 and extended the termination date under the Cigna Merger Agreement, as well as the availability of commitments under the bridge facility and term loan facility, to April 30, 2017. We recorded $108 and $104 of interest expense related to the amortization of the bridge loan facility and other related fees during the years ended December 31, 2017 and 2016, respectively. The commitment of the lenders to provide the bridge facility and term loan facility expired on April 30, 2017.
Convertible Debentures
On October 9, 2012, we issued $1,500 of senior convertible debentures, or the Debentures, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, or the Securities Act. The Debentures are governed by an indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee, or the Indenture. The Debentures bear interest at a rate of 2.750% per year, payable semi-annually in arrears in cash on April 15 and October 15 of each year, and mature on October 15, 2042, unless earlier redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. The Debentures also have a contingent interest feature that will require us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October 15, 2022.
Holders may convert their Debentures at their option prior to the close of business on the business day immediately preceding April 15, 2042, only under the following circumstances: (1) during any fiscal quarter if the last reported sale price of our common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2) during the five business day period after any 10 consecutive trading day period, or the measurement period, in which the trading price per $1,000 (whole dollars) principal amount of Debentures for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the applicable conversion rate on each such day; (3) if we call any or all of the Debentures for redemption, at any time prior to the close of business on the third scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events, as defined in the Indenture. On and after April 15, 2042 and until the close of business on the third scheduled trading day immediately preceding the Debentures’ maturity date of October 15, 2042, holders may convert their Debentures into common stock at any time irrespective of the preceding circumstances. The Debentures are redeemable at our option at any time on or after October 20, 2022, upon the occurrence of certain events, as defined in the Indenture.
Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures converted. With respect to any conversion obligation in excess of the aggregate principal amount of the Debentures converted, we have the option to settle the excess with cash, shares of our common stock or a combination thereof based on a daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures was 13.2319 shares of our common stock per Debenture, which represented a 25% conversion premium based on the closing
-123-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
price of $60.46 per share of our common stock on October 2, 2012 (the date the Debentures’ terms were finalized) and is equivalent to an initial conversion price of $75.575 per share of our common stock.
During the year ended December 31, 2018, $109 aggregate principal amount of the Debentures were surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $402. We recognized a gain on the extinguishment of debt related to the Debentures of $7, based on the fair values of the debt on the conversion settlement dates. During the year ended December 31, 2017, $117 aggregate principal amount of the Debentures was surrendered for conversion. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $345 and recognized a loss on the extinguishment of debt of $2. There were no repurchases or material conversions during the year ended December 31, 2016.
As of December 31, 2018, our common stock was last traded at a price of $262.63 per share. If the remaining Debentures had been converted or matured at December 31, 2018, we would have been obligated to pay the principal of the Debentures plus an amount in cash or shares equal to $757. The Debentures and underlying shares of our common stock have not been and will not be registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
We have accounted for the Debentures in accordance with the cash conversion guidance in FASB guidance for debt with conversion and other options. As a result, the value of the embedded conversion option, net of deferred taxes and equity issuance costs, has been bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets.
The following table summarizes, at December 31, 2018, the related balances, conversion rate and conversion price of the Debentures:
| Outstanding principal amount | $ | 287 | |
| Unamortized debt discount | $ | 93 | |
| Net debt carrying amount | $ | 191 | |
| Equity component carrying amount | $ | 104 | |
| Conversion rate (shares of common stock per $1,000 of principal amount) | 13.8474 | ||
| Effective conversion price (per $1,000 of principal amount) | $ | 72.2151 |
The remaining amortization period of the unamortized debt discount as of December 31, 2018 is approximately 24 years. The unamortized discount will be amortized into interest expense using the effective interest method based on an effective interest rate of 5.130%, which represents the market interest rate for a comparable debt instrument that does not have a conversion feature. During the years ended December 31, 2018, 2017 and 2016, we recognized $12, $17 and $17, respectively, of interest expense related to the Debentures, of which $10, $14 and $14, respectively, represented interest expense recognized at the stated interest rate of 2.750% and $2, $3 and $3, respectively, represented interest expense resulting from amortization of the debt discount.
Total interest paid during 2018, 2017 and 2016 was $728, $778, and $595, respectively.
We were in compliance with all applicable covenants under all of our outstanding debt agreements at December 31, 2018 and 2017.
Future maturities of all long-term debt outstanding at December 31, 2018 are as follows: 2019, $1,546; 2020, $1,585; 2021, $698; 2022, $1,593; 2023, $1,000 and thereafter, $11,644.
- Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to
-124-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at December 31, 2018. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees, or Blue plans, across the country. The cases were consolidated into a single multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the United States District Court for the Northern District of Alabama, or the Court. Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions rules governing the BlueCard and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act, or Sherman Act, and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers, and actions filed in Alabama, Arkansas, California, Florida, Hawaii, Illinois, Indiana, Kansas, Kansas City, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, North Carolina, North Dakota, Oklahoma, Pennsylvania, South Dakota, Rhode Island, South Carolina, Tennessee, Texas, Vermont and Virginia have been consolidated into the multi-district proceeding.
In response to cross motions for partial summary judgment by plaintiffs and defendants, the Court issued an order in April 2018 determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. The Court also found that there remain genuine issues of material fact as to whether defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks. In June 2018, in response to a motion filed by the defendants, the Court certified its April order for interlocutory appeal to the United States Court of Appeals for the Eleventh Circuit, or the Eleventh Circuit. Also in June 2018, the defendants filed, with the Eleventh Circuit Court of Appeals, a petition for permission to appeal the April order, which Plaintiffs opposed. In December 2018, the Eleventh Circuit denied the petition. No dates have been set for either the final pretrial conferences or trials in these actions. We intend to vigorously defend these suits; however, their ultimate outcome cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross), or BCC, was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court, captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, or HCSP, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay
-125-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
a gross premiums tax, or GPT, calculated as 2.35% on gross premiums. As a licensed HCSP, BCC has paid the California Corporate Franchise Tax, or CFT, the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties, for the eight-year period prior to the filing of the complaint.
In March 2018, the Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. We filed a writ of mandate in the California Court of Appeal. The Court of Appeal accepted our writ, and we anticipate that a hearing on our writ will occur in mid-2019. Because GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation. BCC intends to vigorously defend this suit; however, its ultimate outcome cannot be presently determined.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc., or Express Scripts, our vendor for pharmacy benefit management, or PBM, services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York. The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties, or ESI PBM Agreement, over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement between the parties, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) is required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement and that we can terminate the ESI PBM Agreement; and (iv) is required under the PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement; (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith; and (iii) that we do not have the right to terminate the ESI PBM Agreement. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time of the ESI PBM Agreement. In March 2017, the court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. The only remaining claims are for breach of contract and declaratory relief. We intend to vigorously pursue our claims and defend against any counterclaims, which we believe are without merit; however, the ultimate outcome cannot be presently determined.
ERISA Litigation
We are a defendant in a class action lawsuit that was initially filed in June 2016 against Anthem, Inc. and Express Scripts, which has been consolidated into a single multi-district lawsuit captioned In Re Express Scripts/Anthem ERISA Litigation, in the U.S. District Court for the Southern District of New York. The consolidated complaint was filed by plaintiffs against Express Scripts and us on behalf of all persons who are participants in or beneficiaries of any ERISA or non-ERISA healthcare plan from December 1, 2009 to the present in which we provided prescription drug benefits through the ESI PBM Agreement and paid a percentage based co-insurance payment in the course of using that prescription drug benefit. The plaintiffs allege that we breached our duties, either under ERISA or with respect to the implied covenant of good faith and fair dealing implied in the health plans, (i) by failing to adequately monitor Express Scripts’ pricing under the ESI PBM Agreement and (ii) by placing our own pecuniary interest above the best interests of our insureds by allegedly agreeing to higher pricing in the ESI PBM Agreement in exchange for the purchase price for our NextRx PBM business, and (iii) with respect to the non-ERISA members, by negotiating and entering into the ESI PBM Agreement that was allegedly detrimental to the interests of such non-ERISA members. Plaintiffs seek to hold us and Express Scripts jointly and severally liable and to recover all losses suffered by the proposed class, equitable relief, disgorgement of alleged ill-gotten gains, injunctive relief, attorney’s fees and costs and interest.
In April 2017, we filed a motion to dismiss the claims brought against us, and it was granted, without prejudice, in January 2018. Plaintiffs filed a notice of appeal with the United States Court of Appeals for the Second Circuit, which was
-126-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
heard in October 2018. We intend to vigorously defend this suit; however, its ultimate outcome cannot be presently determined.
Cigna Corporation Merger Litigation
In July 2015, we and Cigna announced that we entered into the Cigna Merger Agreement, pursuant to which we would acquire all outstanding shares of Cigna. In July 2016, the U.S. Department of Justice, or DOJ, along with certain state attorneys general, filed a civil antitrust lawsuit in the U.S. District Court for the District of Columbia, or District Court, seeking to block the merger. In February 2017, Cigna purported to terminate the Cigna Merger Agreement and commenced litigation against us in the Delaware Court of Chancery, or Delaware Court, seeking damages, including the $1,850 termination fee pursuant to the terms of the Cigna Merger Agreement, and a declaratory judgment that its purported termination of the Cigna Merger Agreement was lawful, among other claims, which is captioned Cigna Corp. v. Anthem Inc.
Also in February 2017, we initiated our own litigation against Cigna in the Delaware Court seeking a temporary restraining order to enjoin Cigna from terminating the Cigna Merger Agreement, specific performance compelling Cigna to comply with the Cigna Merger Agreement and damages, which is captioned Anthem Inc. v. Cigna Corp. In April 2017, the U.S. Circuit Court of Appeals for the District of Columbia affirmed the ruling of the District Court, which blocked the merger. In May 2017, after the Delaware Court denied our motion to enjoin Cigna from terminating the Cigna Merger Agreement, we delivered to Cigna a notice terminating the Cigna Merger Agreement.
The litigation in Delaware is ongoing with trial scheduled to commence in late February 2019. We believe Cigna’s allegations are without merit and we intend to vigorously pursue our claims and defend against Cigna’s allegations; however, the ultimate outcome of our litigation with Cigna cannot be presently determined.
In October 2018, a shareholder filed a derivative lawsuit in the State of Indiana Marion County Superior Court, captioned Henry Bittmann, Derivatively, et al. v. Joseph R Swedish, et al., purportedly on behalf of Anthem and its shareholders against certain current and former directors and officers alleging breaches of fiduciary duties, unjust enrichment and corporate waste associated with the Cigna Merger Agreement. This case has been stayed at the request of the parties pending the outcome of our litigation with Cigna in the Delaware Court. This lawsuit’s ultimate outcome cannot be presently determined.
U.S. Department of Justice (DOJ) Civil Investigative Demands
Beginning in December 2016, the DOJ has issued civil investigative demands to us to discover information about our chart review and risk adjustment programs under Parts C and D of the Medicare Program. We understand the DOJ is investigating the programs of other Medicare Advantage health plans, along with providers and vendors. We continue to cooperate with the DOJ’s investigation, and the ultimate outcome cannot presently be determined.
Cyber Attack Regulatory Proceedings and Litigation
In February 2015, we reported that we were the target of a sophisticated external cyber attack. The attackers gained unauthorized access to certain of our information technology systems and obtained personal information related to many individuals and employees, such as names, birth dates, healthcare identification/social security numbers, street addresses, email addresses, phone numbers and employment information, including income data. To date, there is no evidence that credit card or medical information, such as claims, test results or diagnostic codes, were targeted, accessed or obtained, although no assurance can be given that we will not identify additional information that was accessed or obtained.
Upon discovery of the cyber attack, we took immediate action to remediate the security vulnerability and retained a cybersecurity firm to evaluate our systems and identify solutions based on the evolving landscape. We have provided credit monitoring and identity protection services to those who have been affected by this cyber attack. We have continued to implement security enhancements since this incident. We have incurred expenses subsequent to the cyber attack to investigate and remediate this matter and expect to continue to incur expenses of this nature in the foreseeable future. We recognize these expenses in the periods in which they are incurred.
Federal and state agencies, including state insurance regulators, state attorneys general, the HHS Office of Civil Rights and the Federal Bureau of Investigation, are investigating, or have investigated, events related to the cyber attack, including how it occurred, its consequences and our responses. In connection with the resolution of the National Association of
-127-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Insurance Commissioners’ multistate targeted market conduct and financial exam in December 2016, we agreed to provide a customized credit protection program, equivalent to a credit freeze, for our members who were under the age of eighteen on January 27, 2015. No fines or penalties were imposed on us. In October 2018, we resolved the investigation by the HHS Office of Civil Rights. The resolution included a monetary settlement along with an agreement to a two-year Corrective Action Plan. Additionally, an ongoing investigation by a multi-state group of Attorneys General remains outstanding. Although we are cooperating in this investigation, we may be subject to additional fines or other obligations, which may have an adverse effect on how we operate our business and an adverse effect on our results of operations and financial condition.
Civil class actions were filed in various federal and state courts by current or former members and others seeking damages that they alleged arose from the cyber attack. In June 2015, the Judicial Panel on Multidistrict Litigation entered an order transferring the consolidated civil actions to the U.S. District Court for the Northern District of California, or the U.S. District Court, in a matter captioned In Re Anthem, Inc. Data Breach Litigation. The parties agreed to settle plaintiffs’ claims on a class-wide basis for a total settlement payment of $115. In August 2017, the U.S. District Court issued an order of preliminary approval of the settlement. The U.S. District Court held hearings on plaintiffs’ motion for final approval and class counsel’s fee petition in February and June 2018 and appointed a special master to review class counsel’s fee petition. Final approval of the settlement was granted by the U.S. District Court in August 2018. All appeals that were filed with the Ninth Circuit Court of Appeals by class-member objections challenging approval of the settlement have been resolved. This matter is now closed. The three state court cases related to the cyber attack that were proceeding outside of this multidistrict litigation have been resolved and dismissed with prejudice.
We have contingency plans and insurance coverage for certain expenses and potential liabilities of this nature and will pursue coverage for all applicable losses; however, the ultimate outcome of our pursuit of insurance coverage cannot be presently determined. We intend to vigorously defend the remaining regulatory actions related to the cyber attack; however, their ultimate outcome cannot be presently determined.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like HMOs and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, PPO and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable settlements of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
Express Scripts, through our ESI PBM Agreement, is the provider of certain PBM services to our plans. In October 2017, we established a new pharmacy benefits manager, called IngenioRx, and entered into a five-year agreement with CaremarkPCS Health, L.L.C., or CVS Health, which is a subsidiary of CVS Health Corporation, to begin offering PBM solutions, or the CVS PBM Agreement. In January 2019, we exercised our contractual right to terminate the ESI PBM Agreement earlier than the original expiration date of December 31, 2019 due to the recent acquisition of Express Scripts by Cigna. As a result of exercising our early termination right, the ESI PBM Agreement will now terminate on March 1, 2019, and the twelve-month transition period provided for in the ESI PBM Agreement to migrate the services begins on March 2, 2019. At that time CVS Health is able to begin providing certain PBM services to IngenioRx, pursuant to the CVS PBM Agreement. Notwithstanding our termination of the ESI PBM Agreement, the litigation between us and Express Scripts
-128-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
regarding the ESI PBM Agreement continues. In March 2016, we filed a lawsuit against Express Scripts seeking to recover damages for pharmacy pricing that is higher than competitive benchmark pricing, damages related to operational breaches, as well as various declarations under the ESI PBM Agreement between the parties. For additional information regarding this lawsuit, refer to the Litigation and Regulatory Proceedings-Express Scripts, Inc. Pharmacy Benefit Management Litigation section above. We believe we have appropriately recognized all rights and obligations under the ESI PBM Agreement as of December 31, 2018.
Vulnerability from Concentrations
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the states in which we conduct business. As of December 31, 2018, there were no significant concentrations of financial instruments in a single investee, industry or geographic location.
- Capital Stock
Stock Incentive Plans
Our Board of Directors has adopted the 2017 Anthem Incentive Compensation Plan, or 2017 Incentive Plan, which has been approved by our shareholders. The term of the 2017 Incentive Plan is such that no awards may be granted on or after May 18, 2027. The 2017 Incentive Plan gives authority to the Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock options, stock, restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance units. The 2017 Incentive Plan limits the number of available shares for issuance to 37.5 shares, subject to adjustment as set forth in the 2017 Incentive Plan.
Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Historically, stock options have vested over three years in equal semi-annual installments and generally have a term of ten years from the grant date. Amendments to the 2017 Incentive Plan, effective July 1, 2018, require future grants of stock options to vest in three equal annual installments.
Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination due to retirement. Our attribution method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which the fair value of the awards will be recognized.
Awards of restricted stock or restricted stock units are issued at the fair value of the stock on the grant date and may also include one or more performance measures that must be met for the award to vest. The restrictions lapse in three equal annual installments. Performance units issued in 2018 will vest in 2021, based on earnings targets over the three year period of 2018 to 2020. Performance units issued in 2017 will vest in 2020, based on earnings targets over the three year period of 2017 to 2019. Performance units issued in 2016 will vest in 2019, based on earnings targets over the three year period of 2016 to 2018.
For the years ended December 31, 2018, 2017 and 2016, we recognized share-based compensation expense of $226, $170 and $165, respectively, as well as related tax benefits of $61, $68 and $61, respectively.
-129-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of stock option activity for the year ended December 31, 2018 is as follows:
| Number of Shares | Weighted-Average Option Price per Share | Weighted-Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | |||||||||
| Outstanding at January 1, 2018 | 4.3 | $ | 124.31 | |||||||||
| Granted | 0.9 | 232.79 | ||||||||||
| Exercised | (1.3 | ) | 112.72 | |||||||||
| Forfeited or expired | (0.2 | ) | 189.52 | |||||||||
| Outstanding at December 31, 2018 | 3.7 | 149.65 | 6.15 | $ | 416 | |||||||
| Exercisable at December 31, 2018 | 2.4 | 125.88 | 5.00 | $ | 331 |
The intrinsic value of options exercised during the years ended December 31, 2018, 2017 and 2016 amounted to $172, $192 and $103, respectively. We recognized tax benefits of $47, $76 and $38 in 2018, 2017 and 2016, respectively, from option exercises and disqualifying dispositions. During the years ended December 31, 2018, 2017 and 2016, we received cash of $141, $200 and $95, respectively, from exercises of stock options.
The total fair value of restricted stock awards that vested during the years ended December 31, 2018, 2017 and 2016 was $237, $127 and $185, respectively.
A summary of the status of nonvested restricted stock activity, including restricted stock units, for the year ended December 31, 2018 is as follows:
| Restricted Stock Shares and Units | Weighted-Average Grant Date Fair Value per Share | |||||
| Nonvested at January 1, 2018 | 2.0 | $ | 152.20 | |||
| Granted | 0.9 | 233.73 | ||||
| Vested | (1.0 | ) | 147.93 | |||
| Forfeited | (0.2 | ) | 188.06 | |||
| Nonvested at December 31, 2018 | 1.7 | 183.32 |
During the year ended December 31, 2018, we granted approximately 0.3 restricted stock units that are contingent upon us achieving earning targets over the three year period of 2018 to 2020. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2020, based on results in the three year period.
During the year ended December 31, 2018, we granted an additional 0.2 restricted stock units, associated with our 2015 grants, that were earned as a result of satisfactory completion of performance measures between 2015 and 2017. These grants and vested shares have been included in the activity shown above.
As of December 31, 2018, the total remaining unrecognized compensation expense related to nonvested stock options and restricted stock, including restricted stock units, amounted to $22 and $136, respectively, which will be amortized over the weighted-average remaining requisite service periods of 11 months and 12 months, respectively.
As of December 31, 2018, there were approximately 26.9 shares of common stock available for future grants under the 2017 Incentive Plan.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice model are based on an analysis of implied volatilities of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model, which
-130-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the multiple-grant approach for recognizing compensation expense associated with each separately vesting portion of the share-based award.
The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December 31, 2018, 2017 and 2016:
| 2018 | 2017 | 2016 | ||||||
| Risk-free interest rate | 2.90 | % | 2.31 | % | 1.76 | % | ||
| Volatility factor | 30.00 | % | 32.00 | % | 32.00 | % | ||
| Dividend yield (annual) | 1.30 | % | 1.60 | % | 2.00 | % | ||
| Weighted-average expected life (years) | 3.70 | 4.00 | 4.10 |
The following weighted-average fair values were determined for the years ending December 31, 2018, 2017 and 2016:
| 2018 | 2017 | 2016 | |||||||||
| Options granted during the year | $ | 55.48 | $ | 40.88 | $ | 30.56 | |||||
| Restricted stock awards granted during the year | 233.73 | 174.44 | 131.81 |
The binomial lattice option-pricing model requires the input of highly subjective assumptions including the expected stock price volatility. Because our stock option grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.
Employee Stock Purchase Plan
We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan, or the Stock Purchase Plan, which is intended to provide a means to encourage and assist employees in acquiring a stock ownership interest in Anthem. Pursuant to the terms of the Stock Purchase Plan, an employee is permitted to purchase no more than $25,000 (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter. Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the stock is accumulated in the employee’s investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a price per share of 95% of the fair value of a share of common stock on the last trading day of the plan quarter. The employee stock purchase plan discount is not recognized as compensation expense based on GAAP guidance. There were 0.2 shares issued during the year ended December 31, 2018. As of December 31, 2018, 5.0 shares were available for issuance under the Stock Purchase Plan.
Effective January 1, 2019, the price per share for the shares purchased under the Stock Purchase Plan will be 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. This additional discount will result in compensation expense beginning in the first quarter of 2019. Participants will be required to hold shares purchased under the Stock Purchase Plan for at least one year from the purchase date.
Use of Capital and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
-131-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of the cash dividend activity for the years ended December 31, 2018 and 2017 is as follows:
| Declaration Date | Record Date | Payment Date | Cash Dividend per Share | Total | ||||||||
| Year ended December 31, 2018 | ||||||||||||
| January 30, 2018 | March 9, 2018 | March 23, 2018 | $ | 0.75 | $ | 192 | ||||||
| April 24, 2018 | June 8, 2018 | June 25, 2018 | 0.75 | 196 | ||||||||
| July 24, 2018 | September 10, 2018 | September 25, 2018 | 0.75 | 195 | ||||||||
| October 30, 2018 | December 5, 2018 | December 21, 2018 | 0.75 | 193 | ||||||||
| Year ended December 31, 2017 | ||||||||||||
| February 22, 2017 | March 10, 2017 | March 24, 2017 | $ | 0.65 | $ | 172 | ||||||
| April 27, 2017 | June 9, 2017 | June 23, 2017 | 0.65 | 172 | ||||||||
| July 25, 2017 | September 8, 2017 | September 25, 2017 | 0.70 | 181 | ||||||||
| October 24, 2017 | December 5, 2017 | December 21, 2017 | 0.70 | 180 |
On January 29, 2019, our Audit Committee declared a quarterly cash dividend to shareholders of $0.80 per share on the outstanding shares of our common stock. This quarterly dividend is payable on March 29, 2019 to the shareholders of record as of March 18, 2019.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On December 7, 2017, the Board of Directors authorized a $5,000 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the period January 1, 2019 through February 7, 2019 (subsequent to December 31, 2018) and for the years ended December 31, 2018 and 2017 is as follows:
| January 1, 2019 through February 7, 2019 | Years Ended December 31 | ||||||||||
| 2018 | 2017 | ||||||||||
| Shares repurchased | 0.6 | 6.8 | 10.5 | ||||||||
| Average price per share | $ | 261.26 | $ | 248.34 | $ | 189.93 | |||||
| Aggregate cost | $ | 165 | $ | 1,685 | $ | 1,998 | |||||
| Authorization remaining at end of year | $ | 5,328 | $ | 5,493 | $ | 7,178 |
We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry conditions.
For additional information regarding the use of capital for debt security repurchases, see Note 12, “Debt.”
-132-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
- Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at December 31, 2018 and 2017 is as follows:
| 2018 | 2017 | ||||||
| Investments: | |||||||
| Gross unrealized gains | $ | 173 | $ | 940 | |||
| Gross unrealized losses | (371 | ) | (105 | ) | |||
| Net pretax unrealized (losses) gains | (198 | ) | 835 | ||||
| Deferred tax asset (liability) | 39 | (301 | ) | ||||
| Net unrealized (losses) gains on investments | (159 | ) | 534 | ||||
| Non-credit components of OTTI on investments: | |||||||
| Gross unrealized losses | (3 | ) | — | ||||
| Deferred tax asset | 1 | — | |||||
| Net unrealized non-credit component of OTTI on investments | (2 | ) | — | ||||
| Cash flow hedges: | |||||||
| Gross unrealized losses | (311 | ) | (359 | ) | |||
| Deferred tax asset | 65 | 126 | |||||
| Net unrealized losses on cash flow hedges | (246 | ) | (233 | ) | |||
| Defined benefit pension plans: | |||||||
| Deferred net actuarial loss | (751 | ) | (625 | ) | |||
| Deferred prior service cost | (1 | ) | (1 | ) | |||
| Deferred tax asset | 193 | 244 | |||||
| Net unrecognized periodic benefit costs for defined benefit pension plans | (559 | ) | (382 | ) | |||
| Postretirement benefit plans: | |||||||
| Deferred net actuarial loss | (58 | ) | (77 | ) | |||
| Deferred prior service credits | 34 | 46 | |||||
| Deferred tax asset | 6 | 12 | |||||
| Net unrecognized periodic benefit costs for postretirement benefit plans | (18 | ) | (19 | ) | |||
| Foreign currency translation adjustments: | |||||||
| Gross unrealized losses | (3 | ) | (2 | ) | |||
| Deferred tax asset | 1 | 1 | |||||
| Net unrealized losses on foreign currency translation adjustments | (2 | ) | (1 | ) | |||
| Accumulated other comprehensive loss | $ | (986 | ) | $ | (101 | ) |
We adopted the FASB standard on accounting for non-consolidated equity investments (ASU 2016-01) on January 1, 2018 as a cumulative-effect adjustment and reclassified $320 of unrealized gains on equity investments, net of tax, from accumulated other comprehensive loss to retained earnings on our consolidated balance sheet. We also adopted the FASB standard on reclassification of certain tax effects from accumulated other comprehensive income (ASU 2018-02) on January 1, 2018 and reclassified $91 of stranded tax effects from accumulated other comprehensive loss to retained earnings on our consolidated balance sheet. See Note 2, “Basis of Presentation and Significant Accounting Policies – Recently Adopted Accounting Guidance” for further information on these standards.
-133-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Other comprehensive income (loss) reclassification adjustments for the years ended December 31, 2018, 2017 and 2016 are as follows:
| 2018 | 2017 | 2016 | |||||||||
| Investments: | |||||||||||
| Net holding (loss) gain on investment securities arising during the period, net of tax benefit (expense) of $133, ($153), and ($119), respectively | $ | (465 | ) | $ | 280 | $ | 186 | ||||
| Reclassification adjustment for net realized loss (gain) on investment securities, net of tax (benefit) expense of $(13), $58, and $37, respectively | 47 | (107 | ) | (68 | ) | ||||||
| Total reclassification adjustment on investments | (418 | ) | 173 | 118 | |||||||
| Non-credit component of OTTI on investments: | |||||||||||
| Non-credit component of OTTI on investments, net of tax benefit (expense) of $1, ($3), and ($3), respectively | (2 | ) | 4 | 5 | |||||||
| Cash flow hedges: | |||||||||||
| Holding gain (loss), net of tax (expense) benefit of $(10), $35, and $47, respectively | 37 | (65 | ) | (87 | ) | ||||||
| Other: | |||||||||||
| Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax benefit (expense) of $29, $(35), and $5, respectively | (90 | ) | 51 | (13 | ) | ||||||
| Foreign currency translation adjustment, net of tax expense of $0, ($1), and ($1), respectively | (1 | ) | 3 | 2 | |||||||
| Net (loss) gain recognized in other comprehensive loss, net of tax benefit (expense) of $140, ($99), and ($34), respectively | $ | (474 | ) | $ | 166 | $ | 25 |
- Reinsurance
We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations. In conjunction with the ACA temporary reinsurance premium stabilization program that was effective for 2014 through 2016, we recognized assessments upon our fully-insured non-grandfathered individual market plans that were eligible for reinsurance recoveries as ceded premiums and estimated reinsurance recoveries as a reduction to benefit expense. Assessments upon all other lines of business that were not eligible for reinsurance recoveries were recognized in selling, general and administrative expense.
A summary of direct, assumed and ceded premiums written and earned for the years ended December 31, 2018, 2017 and 2016 is as follows:
| 2018 | 2017 | 2016 | |||||||||||||||||||||
| Written | Earned | Written | Earned | Written | Earned | ||||||||||||||||||
| Direct | $ | 84,835 | $ | 85,213 | $ | 83,974 | $ | 83,418 | $ | 78,200 | $ | 78,726 | |||||||||||
| Assumed | 264 | 259 | 275 | 275 | 217 | 217 | |||||||||||||||||
| Ceded | (51 | ) | (51 | ) | (44 | ) | (45 | ) | (80 | ) | (83 | ) | |||||||||||
| Net premiums | $ | 85,048 | $ | 85,421 | $ | 84,205 | $ | 83,648 | $ | 78,337 | $ | 78,860 | |||||||||||
| Percentage—assumed to net premiums | 0.3 | % | 0.3 | % | 0.3 | % | 0.3 | % | 0.3 | % | 0.3 | % |
-134-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of net premiums written and earned by segment (see Note 19, “Segment Information”) for the years ended December 31, 2018, 2017 and 2016 is as follows:
| 2018 | 2017 | 2016 | |||||||||||||||||||||
| Written | Earned | Written | Earned | Written | Earned | ||||||||||||||||||
| Reportable segments: | |||||||||||||||||||||||
| Commercial & Specialty Business | $ | 30,661 | $ | 30,532 | $ | 35,382 | $ | 35,503 | $ | 33,101 | $ | 33,577 | |||||||||||
| Government Business | 54,387 | 54,889 | 48,823 | 48,145 | 45,236 | 45,283 | |||||||||||||||||
| Net premiums | $ | 85,048 | $ | 85,421 | $ | 84,205 | $ | 83,648 | $ | 78,337 | $ | 78,860 |
The effect of reinsurance on benefit expense for the years ended December 31, 2018, 2017 and 2016 is as follows:
| 2018 | 2017 | 2016 | |||||||||
| Direct | $ | 71,749 | $ | 72,135 | $ | 67,222 | |||||
| Assumed | 219 | 217 | 184 | ||||||||
| Ceded | (73 | ) | (116 | ) | (572 | ) | |||||
| Net benefit expense | $ | 71,895 | $ | 72,236 | $ | 66,834 |
The effect of reinsurance on certain assets and liabilities at December 31, 2018 and 2017 is as follows:
| 2018 | 2017 | ||||||
| Policy liabilities, assumed | $ | 50 | $ | 54 | |||
| Unearned income, assumed | 6 | 1 | |||||
| Premiums payable, ceded | 17 | 9 | |||||
| Premiums receivable, assumed | 37 | 33 |
- Leases
We lease office space and certain computer and related equipment using noncancelable operating leases. At December 31, 2018, future lease payments for operating leases with initial or remaining noncancelable terms of one year or more consisted of the following:
| 2019 | $ | 192 | |
| 2020 | 165 | ||
| 2021 | 139 | ||
| 2022 | 127 | ||
| 2023 | 109 | ||
| Thereafter | 385 | ||
| Total minimum payments required | $ | 1,117 |
We have certain lease agreements that contain contingent payment provisions. Under these provisions, we pay contingent amounts in addition to base rent, primarily based upon annual changes in the consumer price index. The schedule above contains estimated amounts for potential future increases in lease payments based on the contingent payment provisions.
Lease expense for 2018, 2017 and 2016 was $207, $205 and $207, respectively.
-135-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
- Earnings per Share
The denominator for basic and diluted earnings per share at December 31, 2018, 2017 and 2016 is as follows:
| 2018 | 2017 | 2016 | ||||||
| Denominator for basic earnings per share—weighted-average shares | 258.1 | 261.5 | 262.9 | |||||
| Effect of dilutive securities—employee stock options, non-vested restricted stock awards, convertible debentures and equity units | 6.1 | 6.3 | 5.2 | |||||
| Denominator for diluted earnings per share | 264.2 | 267.8 | 268.1 |
During the years ended December 31, 2018, 2017 and 2016, weighted-average shares related to certain stock options of 0.3, 0.4 and 2.2, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. The Equity Unit purchase contracts were settled in May 2018, and approximately 6.0 shares of our common stock were issued and included in the basic earnings per share calculation.
During the years ended December 31, 2018, 2017 and 2016, we issued approximately 0.3, 0.4 and 0.5 restricted stock units, respectively, of which vesting was contingent upon us meeting certain earnings targets. Contingent restricted stock units are excluded from the denominator for diluted earnings per share and are included only if and when the contingency is met. The 2018 contingent restricted stock units are being measured over the three year period of 2018 through 2020, the 2017 contingent restricted stock units are being measured over the three year period of 2017 through 2019 and the 2016 contingent restricted stock units are being measured over the three year period of 2016 through 2018. Contingent restricted stock units vest in March of the year following each measurement period.
- Segment Information
Our organizational structure is comprised of three reportable segments: Commercial & Specialty Business; Government Business; and Other.
Our Commercial & Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the Commercial & Specialty Business segment offer fully-insured health products; provide a broad array of managed care services to self-funded customers including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services; and provide an array of specialty and other insurance products and services such as dental, vision, life and disability insurance benefits.
Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, or NGS, and services provided to the federal government in connection with FEP®. Our Medicare business includes services such as Medicare Supplement plans; Medicare Advantage, including Special Needs Plans; Medicare Part D; and dual-eligible programs through Medicare-Medicaid Plans. Our Medicaid business includes our managed care alternatives through publicly funded healthcare programs, including Medicaid, ACA-related Medicaid expansion programs, Temporary Assistance for Needy Families programs, programs for seniors and people with disabilities, Children’s Health Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities or developmental disabilities. NGS acts as a Medicare contractor for the federal government in several regions across the nation.
Our Other segment includes certain eliminations and corporate expenses not allocated to either of our other reportable segments.
We define operating revenues to include premium income and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefit products. Operating gain, a non-GAAP measure, is calculated as total operating revenue less benefit expense and selling, general and administrative expense.
Through our participation in various federal government programs, we generated approximately 19.8%, 17.8% and 18.2% of our total consolidated revenues from agencies of the U.S. government for the years ended December 31, 2018, 2017, and 2016, respectively. These revenues are contained in the Government Business segment.
-136-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, “Basis of Presentation and Significant Accounting Policies,” except that certain shared administrative expenses for each segment are recognized on a pro rata allocated basis, which in the aggregate approximates the consolidated expense. Any difference between the allocated expenses and actual consolidated expense is included in other expenses not allocated to reportable segments. Intersegment sales and expenses are recorded at cost and eliminated in the consolidated financial statements. We evaluate performance of the reportable segments based on operating gain or loss as defined above. We evaluate net investment income, net realized gains on financial instruments, OTTI losses recognized in income, interest expense, amortization expense, gain or loss on extinguishment of debt, income taxes, assets and liabilities on a consolidated basis as these items are managed in a corporate shared service environment and are not the responsibility of segment operating management.
During the fourth quarter of 2018, we reclassified certain ancillary businesses to align how our segments are currently being managed. Prior year amounts have been reclassified for comparability.
Financial data by reportable segment for the years ended December 31, 2018, 2017 and 2016 is as follows:
| Commercial & Specialty Business | Government Business | Other | Total | ||||||||||||
| Year ended December 31, 2018 | |||||||||||||||
| Operating revenue | $ | 35,782 | $ | 55,567 | $ | (8 | ) | $ | 91,341 | ||||||
| Operating gain (loss) | 3,629 | 1,895 | (98 | ) | 5,426 | ||||||||||
| Depreciation and amortization of property and equipment | — | — | 652 | 652 | |||||||||||
| Year ended December 31, 2017 | |||||||||||||||
| Operating revenue | $ | 40,363 | $ | 48,702 | $ | (4 | ) | $ | 89,061 | ||||||
| Operating gain (loss) | 2,847 | 1,445 | (117 | ) | 4,175 | ||||||||||
| Depreciation and amortization of property and equipment | — | — | 601 | 601 | |||||||||||
| Year ended December 31, 2016 | |||||||||||||||
| Operating revenue | $ | 38,347 | $ | 45,850 | $ | (3 | ) | $ | 84,194 | ||||||
| Operating gain (loss) | 3,148 | 1,827 | (174 | ) | 4,801 | ||||||||||
| Depreciation and amortization of property and equipment | — | — | 576 | 576 |
The major product revenues for each of the reportable segments for the years ended December 31, 2018, 2017 and 2016 are as follows:
| 2018 | 2017 | 2016 | |||||||||
| Commercial & Specialty Business | |||||||||||
| Managed care products | $ | 29,013 | $ | 33,971 | $ | 32,134 | |||||
| Managed care services | 5,115 | 4,732 | 4,616 | ||||||||
| Dental/Vision products and services | 1,220 | 1,218 | 1,182 | ||||||||
| Other | 434 | 442 | 415 | ||||||||
| Total Commercial & Specialty Business | 35,782 | 40,363 | 38,347 | ||||||||
| Government Business | |||||||||||
| Managed care products | 54,889 | 48,145 | 45,283 | ||||||||
| Managed care services | 678 | 557 | 567 | ||||||||
| Total Government Business | 55,567 | 48,702 | 45,850 | ||||||||
| Other | |||||||||||
| Other | (8 | ) | (4 | ) | (3 | ) | |||||
| Total product revenues | $ | 91,341 | $ | 89,061 | $ | 84,194 |
-137-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.
Asset, liability and equity details by reportable segment have not been disclosed, as we do not internally report such information.
A reconciliation of reportable segment operating revenues to the amounts of total revenues included in the consolidated statements of income for the years ended December 31, 2018, 2017 and 2016 is as follows:
| 2018 | 2017 | 2016 | |||||||||
| Reportable segments operating revenues | $ | 91,341 | $ | 89,061 | $ | 84,194 | |||||
| Net investment income | 970 | 867 | 779 | ||||||||
| Net realized (losses) gains on financial instruments | (180 | ) | 145 | 5 | |||||||
| Other-than-temporary impairment losses recognized in income | (26 | ) | (33 | ) | (115 | ) | |||||
| Total revenues | $ | 92,105 | $ | 90,040 | $ | 84,863 |
A reconciliation of reportable segment operating gain to income before income tax expense included in the consolidated statements of income for the years ended December 31, 2018, 2017 and 2016 is as follows:
| 2018 | 2017 | 2016 | |||||||||
| Reportable segments operating gain | $ | 5,426 | $ | 4,175 | $ | 4,801 | |||||
| Net investment income | 970 | 867 | 779 | ||||||||
| Net realized (losses) gains on financial instruments | (180 | ) | 145 | 5 | |||||||
| Other-than-temporary impairment losses recognized in income | (26 | ) | (33 | ) | (115 | ) | |||||
| Interest expense | (753 | ) | (739 | ) | (723 | ) | |||||
| Amortization of other intangible assets | (358 | ) | (169 | ) | (192 | ) | |||||
| Loss on extinguishment of debt | (11 | ) | (282 | ) | — | ||||||
| Income before income tax expense | $ | 5,068 | $ | 3,964 | $ | 4,555 |
- Related Party Transactions
We have a 19.50% equity investment in National Accounts Service Company, LLC, or NASCO, which processes National Accounts claims and provides other administrative services for us and certain other Blue Cross Blue Shield plans. Administrative expenses incurred related to NASCO services totaled $79, $73 and $80, for the years ended December 31, 2018, 2017 and 2016, respectively. Amounts due to NASCO were $5 and $6 at December 31, 2018 and 2017, respectively.
- Statutory Information
The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance regulatory authorities, commonly referred to as statutory accounting, which vary in certain respects from GAAP. However, certain of our insurance and HMO subsidiaries, including BCC, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc. and CareMore Health Plan are regulated by the California Department of Managed Health Care, or DMHC, and report their accounts in conformity with GAAP (these entities are collectively referred to as the “DMHC regulated entities”). Typical differences of GAAP reporting as compared to statutory reporting are the inclusion of unrealized gains or losses relating to fixed maturity securities in shareholders’ equity, recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory limits. The National Association of Insurance Commissioners, or NAIC, developed a codified version of the statutory accounting principles, designed to foster more consistency among the states for accounting guidelines and reporting. Prescribed statutory accounting practices are set forth in a variety of publications of the NAIC as well as state laws, regulations and general administrative rules.
-138-
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary’s domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC.
Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital, or RBC, requirements. RBC is a method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its size and risk profile. The formula for determining the amount of RBC specifies various factors, weighted based on the perceived degree of risk, which are applied to certain financial balances and financial activity. Below minimum RBC requirements are classified within certain levels, each of which requires specified corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December 31, 2018 and 2017, all of our regulated subsidiaries exceeded the minimum RBC requirements and/or capital and solvency requirements of their applicable governmental regulator. The statutory RBC necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was approximately $4,800 and $4,700 as of December 31, 2018 and 2017, respectively. The tangible net equity required for the DMHC regulated entities was approximately $570 and $670 as of December 31, 2018 and 2017, respectively.
Statutory-basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries, excluding the DMHC regulated entities, was $12,038 and $11,666 at December 31, 2018 and 2017, respectively. Statutory-basis net income of our insurance and HMO subsidiaries and net income of our other regulated subsidiaries, excluding the DMHC regulated entities, was $3,412, $2,674 and $2,613 for 2018, 2017 and 2016, respectively. GAAP equity of the DMHC regulated entities was $3,125 and $2,917 at December 31, 2018 and 2017, respectively. GAAP net income of the DMHC regulated entities was $789, $1,047 and $775 for the years ended December 31, 2018, 2017 and 2016, respectively.
- Selected Quarterly Financial Data (Unaudited)
Selected quarterly financial data is as follows:
| For the Quarter Ended | |||||||||||||||
| March 31 | June 30 | September 30 | December 31 | ||||||||||||
| 2018 | |||||||||||||||
| Total revenues | $ | 22,537 | $ | 22,944 | $ | 23,251 | $ | 23,373 | |||||||
| Income before income tax expense | 1,780 | 1,504 | 1,242 | 542 | |||||||||||
| Net income | 1,312 | 1,054 | 960 | 424 | |||||||||||
| Basic net income per share | $ | 5.13 | $ | 4.07 | $ | 3.70 | $ | 1.64 | |||||||
| Diluted net income per share | 4.99 | 3.98 | 3.62 | 1.61 | |||||||||||
| 2017 | |||||||||||||||
| Total revenues | $ | 22,525 | $ | 22,407 | $ | 22,426 | $ | 22,682 | |||||||
| Income before income tax expense | 1,514 | 1,205 | 1,119 | 126 | |||||||||||
| Net income | 1,009 | 855 | 747 | 1,232 | |||||||||||
| Basic net income per share | $ | 3.82 | $ | 3.23 | $ | 2.87 | $ | 4.80 | |||||||
| Diluted net income per share | 3.73 | 3.16 | 2.80 | 4.67 |
Previous: Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. · Next: Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.